,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,155,1,1,,67116,338,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
1,157,1,1,,67116,338,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
2,161,1,1,,67116,338,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
3,165,1,1,,67116,338,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
4,167,1,1,,67116,338,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
5,175,1,1,,67116,338,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
6,179,1,1,,67116,338,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
7,248,1,1,,67116,338,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
8,485,1,8,,8139912,338,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
9,568,1,7,,8139912,338,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
10,568,1,7,,8139912,338,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
11,583,2,6,,8139912,338,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
12,598,1,4,,8139912,338,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
13,602,1,4,,8139912,338,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
14,606,1,3,,8139912,338,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
15,606,1,3,,8139912,338,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
16,618,2,6,,8139912,338,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
17,620,2,5,,8139912,338,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
18,629,1,3,,8139912,338,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
19,630,1,1,,8139912,338,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
20,631,1,4,,8139912,338,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
21,631,1,4,,8139912,338,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
22,633,1,3,,8139912,338,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
23,639,1,2,,8139912,338,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
24,648,1,3,,8139912,338,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
25,687,1,17,,8139912,338,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
26,701,1,17,,8139912,338,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
27,719,1,3,,8139912,338,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
28,731,1,5,,8139912,338,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
29,731,1,5,,8139912,338,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
30,741,1,4,,8139912,338,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance - Dose Response,Confirmatory,,
31,747,1,1,,24715046,338,Unspecified,4885617.0,6783.0,,,Basic StarGazer Assay on Human SULT1E1,Other,,
32,750,1,3,,8139912,338,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
33,757,1,4,,8139912,338,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
34,758,1,4,,8139912,338,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
35,759,1,4,,8139912,338,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
36,760,1,4,,8139912,338,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
37,761,1,4,,8139912,338,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
38,764,1,4,,8139912,338,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
39,775,1,3,,8139912,338,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
40,781,1,1,,8139912,338,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
41,782,1,2,,8139912,338,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
42,782,1,2,,8139912,338,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
43,793,1,2,,8139912,338,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
44,797,1,1,,8139912,338,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
45,798,2,12,,8139912,338,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
46,799,1,5,,8139912,338,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
47,800,2,11,,8139912,338,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
48,803,1,4,,8139912,338,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
49,804,1,3,,8139912,338,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
50,817,1,1,,8139912,338,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
51,818,1,2,,8139912,338,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
52,827,1,2,,8139912,338,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
53,828,1,5,,8139912,338,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
54,834,1,3,,8139912,338,Inactive,,,,,C. albicans biofilm killing,Screening,,
55,841,1,1,,8139912,338,Active,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
56,861,1,1,,8139912,338,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
57,862,1,2,,8139912,338,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
58,868,1,3,,8139912,338,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
59,871,1,2,,8139912,338,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
60,873,1,13,,8139912,338,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
61,878,1,2,,8139912,338,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
62,880,2,1,,8139912,338,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
63,880,2,1,,8139912,338,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
64,880,2,1,,29215390,338,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
65,880,2,1,,29215390,338,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
66,881,2,2,,29215390,338,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
67,894,2,1,,8139912,338,Inconclusive,31542939.0,3248.0,31.6228,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
68,894,2,1,,29215390,338,Inconclusive,31542939.0,3248.0,28.1838,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
69,898,1,1,,8139912,338,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
70,920,1,2,,8139912,338,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
71,932,1,4,,8139912,338,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
72,940,1,2,,8139912,338,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
73,950,1,1,,8139912,338,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
74,951,1,1,,8139912,338,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
75,952,1,1,,8139912,338,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
76,999,1,1,,46487944,338,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor Using a Diverse Compound Set,Screening,,
77,1001,2,2,,8139912,338,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
78,1004,1,1,,46487944,338,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression Using a Diverse Compound Set,Screening,,
79,1006,1,6,,8139912,338,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
80,1007,1,1,,8139912,338,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
81,1008,1,2,,8139912,338,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
82,1009,1,2,,8139912,338,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
83,1012,1,4,,8139912,338,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
84,1016,1,4,,8139912,338,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
85,1018,2,5,,8139912,338,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
86,1019,1,4,,8139912,338,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
87,1020,1,5,,8139912,338,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
88,1021,1,1,,8139912,338,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
89,1022,1,1,,8139912,338,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
90,1027,1,3,,8139912,338,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
91,1030,2,1,,8139912,338,Inconclusive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
92,1030,2,1,,29215390,338,Inconclusive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
93,1032,1,2,,8139912,338,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
94,1032,1,2,,8139912,338,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
95,1040,1,2,,8139912,338,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
96,1046,1,6,,8139912,338,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
97,1048,1,1,,8139912,338,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
98,1048,1,1,,8139912,338,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
99,1049,1,1,,8139912,338,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
100,1049,1,1,,8139912,338,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
101,1051,1,1,,8139912,338,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
102,1051,1,1,,8139912,338,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
103,1063,1,1,,8139912,338,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
104,1066,1,2,,8139912,338,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
105,1085,1,1,,8139912,338,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
106,1135,1,3,,8139912,338,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
107,1136,1,3,,8139912,338,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
108,1203,1,3,,8139912,338,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
109,1209,2,2,,8139912,338,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
110,1214,1,4,,8139912,338,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
111,1216,1,5,,8139912,338,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
112,1217,1,4,,8139912,338,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
113,1220,2,2,,8139912,338,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
114,1222,1,6,,8139912,338,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
115,1229,1,3,,8139912,338,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
116,1236,1,1,,8139912,338,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
117,1239,1,3,,8139912,338,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
118,1239,1,3,,8139912,338,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
119,1242,1,1,,8139912,338,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
120,1251,1,1,,8139912,338,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
121,1273,1,1,,8139912,338,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
122,1274,1,2,,8139912,338,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
123,1276,1,1,,8139912,338,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
124,1285,1,1,,8139912,338,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
125,1296,1,1,,8139912,338,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
126,1304,1,2,,8139912,338,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
127,1321,1,2,,8139912,338,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
128,1325,1,2,,8139912,338,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
129,1326,1,4,,8139912,338,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
130,1359,1,4,,8139912,338,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
131,1362,1,2,,8139912,338,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
132,1376,1,2,,8139912,338,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
133,1377,1,1,,8139912,338,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
134,1379,1,2,,8139912,338,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
135,1379,1,2,,29215390,338,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
136,1381,1,1,,8139912,338,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
137,1385,2,2,,8139912,338,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
138,1415,1,2,,8139912,338,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
139,1415,1,2,,8139912,338,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
140,1416,1,2,,8139912,338,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
141,1422,1,1,,8139912,338,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
142,1423,1,2,,8139912,338,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
143,1423,1,2,,8139912,338,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
144,1424,1,1,,8139912,338,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
145,1430,1,1,,8139912,338,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
146,1434,2,3,,8139912,338,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
147,1434,2,3,,8139912,338,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
148,1439,1,1,,8139912,338,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
149,1439,1,1,,8139912,338,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
150,1440,1,1,,8139912,338,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
151,1440,1,1,,8139912,338,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
152,1441,1,1,,8139912,338,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
153,1441,1,1,,8139912,338,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
154,1443,1,3,,8139912,338,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
155,1445,1,1,,8139912,338,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
156,1446,1,3,,8139912,338,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
157,1448,1,3,,8139912,338,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
158,1452,1,1,,8139912,338,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
159,1452,1,1,,29215390,338,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
160,1454,1,1,,8139912,338,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
161,1456,1,1,,8139912,338,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
162,1457,1,1,,8139912,338,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
163,1457,1,1,,29215390,338,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
164,1458,1,1,,8139912,338,Inactive,10937869.0,6607.0,35.4813,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
165,1460,1,3,,8139912,338,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
166,1460,1,3,,29215390,338,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
167,1461,1,2,,8139912,338,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
168,1463,1,1,,8139912,338,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
169,1463,1,1,,29215390,338,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
170,1465,1,1,,8139912,338,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
171,1466,1,2,,8139912,338,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
172,1467,1,3,,29215390,338,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
173,1468,1,1,,8139912,338,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
174,1468,1,1,,29215390,338,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
175,1469,1,1,,8139912,338,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
176,1469,1,1,,29215390,338,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
177,1471,2,1,,29215390,338,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
178,1476,2,1,,8139912,338,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
179,1476,2,1,,29215390,338,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
180,1477,1,1,,8139912,338,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
181,1477,1,1,,29215390,338,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
182,1478,2,1,,8139912,338,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
183,1478,2,1,,29215390,338,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
184,1479,1,2,,8139912,338,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
185,1479,1,2,,29215390,338,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
186,1481,1,2,,8139912,338,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
187,1486,1,3,,8139912,338,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
188,1487,1,1,,8139912,338,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
189,1490,2,1,,8139912,338,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
190,1490,2,1,,29215390,338,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
191,1496,1,4,,8139912,338,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
192,1496,1,4,,8139912,338,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
193,1509,1,2,,8139912,338,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
194,1510,1,3,,8139912,338,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
195,1511,1,3,,8139912,338,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
196,1515,1,2,,8139912,338,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
197,1527,1,3,,8139912,338,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
198,1529,1,1,,8139912,338,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
199,1530,1,1,,8139912,338,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
200,1531,1,1,,8139912,338,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
201,1532,1,1,,8139912,338,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
202,1554,1,1,,8139912,338,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
203,1556,1,4,,8139912,338,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
204,1565,2,2,,8139912,338,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
205,1566,2,3,,8139912,338,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
206,1578,3,2,,8139912,338,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
207,1619,1,2,,8139912,338,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
208,1621,1,2,,8139912,338,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
209,1626,1,2,,8139912,338,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
210,1631,3,1,,8139912,338,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
211,1634,3,1,,8139912,338,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
212,1654,2,2,,8139912,338,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
213,1656,2,2,,8139912,338,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
214,1662,1,2,,8139912,338,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
215,1663,1,2,,8139912,338,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
216,1665,2,2,,8139912,338,Inactive,4503131.0,1499.0,,IC50_Mean,High Throughput Imaging Assay for Beta-Catenin,Confirmatory,,
217,1672,1,3,,8139912,338,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
218,1688,1,1,,8139912,338,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
219,1700,1,2,,8139912,338,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
220,1706,1,2,,8139912,338,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
221,1721,1,2,,8139912,338,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
222,1722,1,2,,8139912,338,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
223,1766,1,1,,8139912,338,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
224,1766,1,1,,8139912,338,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
225,1766,1,1,,29215390,338,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
226,1766,1,1,,29215390,338,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
227,1768,1,1,,8139912,338,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
228,1768,1,1,,8139912,338,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
229,1768,1,1,,29215390,338,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
230,1768,1,1,,29215390,338,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
231,1775,1,2,,8139912,338,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
232,1776,1,2,,8139912,338,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
233,1777,3,2,,8139912,338,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
234,1778,3,3,,8139912,338,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
235,1779,2,2,,8139912,338,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
236,1789,1,2,,8139912,338,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
237,1800,1,2,,8139912,338,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
238,1813,1,2,,8139912,338,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
239,1814,1,2,,8139912,338,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
240,1817,2,2,,8139912,338,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
241,1822,1,3,,8139912,338,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
242,1825,1,1,,8139912,338,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
243,1832,2,1,,8139912,338,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
244,1845,1,2,,8139912,338,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
245,1850,2,1,,8139912,338,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
246,1861,2,1,,8139912,338,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
247,1862,1,4,,8139912,338,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
248,1863,2,1,,8139912,338,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
249,1865,1,1,,8139912,338,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
250,1865,1,1,,29215390,338,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
251,1867,1,4,,8139912,338,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
252,1868,1,4,,8139912,338,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
253,1870,1,4,,8139912,338,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
254,1873,1,4,,8139912,338,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
255,1875,2,1,,8139912,338,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
256,1885,2,1,,8139912,338,Inconclusive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
257,1887,1,4,,8139912,338,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
258,1899,1,3,,8139912,338,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
259,1903,2,3,,8139912,338,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
260,1906,1,3,,8139912,338,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
261,1910,1,2,,8139912,338,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
262,1947,1,2,,8139912,338,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
263,1948,1,1,,29215390,338,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
264,1950,1,3,,8139912,338,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
265,1956,1,1,,8139912,338,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
266,1961,2,2,,8139912,338,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
267,1962,1,2,,8139912,338,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
268,1974,1,2,,8139912,338,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
269,1979,1,1,,8139912,338,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
270,1984,1,3,,8139912,338,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
271,1986,1,2,,8139912,338,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
272,1987,1,2,,8139912,338,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
273,2006,3,2,,8139912,338,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
274,2006,3,2,,8139912,338,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
275,2006,3,2,,8139912,338,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
276,2012,3,2,,8139912,338,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
277,2013,2,2,,8139912,338,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
278,2014,3,2,,8139912,338,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
279,2016,1,3,,8139912,338,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
280,2023,1,3,,8139912,338,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
281,2025,1,3,,8139912,338,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
282,2029,1,3,,8139912,338,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
283,2052,2,1,,8139912,338,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
284,2057,1,2,,8139912,338,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
285,2058,3,2,,8139912,338,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
286,2066,1,4,,8139912,338,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
287,2071,2,2,,8139912,338,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
288,2073,2,3,,8139912,338,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
289,2073,2,3,,8139912,338,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
290,2094,1,2,,8139912,338,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
291,2094,1,2,,8139912,338,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
292,2094,1,2,,8139912,338,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
293,2097,1,2,,8139912,338,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
294,2098,1,1,,8139912,338,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
295,2099,1,1,,8139912,338,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
296,2100,1,1,,8139912,338,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
297,2101,1,1,,8139912,338,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
298,2101,1,1,,29215390,338,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
299,2107,1,1,,8139912,338,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
300,2107,1,1,,29215390,338,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
301,2112,1,1,,8139912,338,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
302,2112,1,1,,29215390,338,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
303,2129,1,2,,8139912,338,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
304,2130,1,3,,8139912,338,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
305,2147,1,1,,8139912,338,Inconclusive,221046486.0,,28.1838,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
306,2156,2,2,,8139912,338,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
307,2174,1,3,,8139912,338,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
308,2177,1,3,,8139912,338,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
309,2205,1,1,,8139912,338,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
310,2216,1,3,,8139912,338,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
311,2221,1,2,,8139912,338,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
312,2227,1,2,,8139912,338,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
313,2234,1,2,,8139912,338,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
314,2235,1,2,,8139912,338,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
315,2237,1,2,,8139912,338,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
316,2239,1,2,,8139912,338,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
317,2242,1,1,,8139912,338,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
318,2247,1,2,,8139912,338,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
319,2280,2,3,,8139912,338,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
320,2288,1,1,,8139912,338,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
321,2289,1,1,,8139912,338,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
322,2300,1,3,,8139912,338,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
323,2314,1,2,,8139912,338,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
324,2314,1,2,,8139912,338,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
325,2314,1,2,,29215390,338,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
326,2314,1,2,,29215390,338,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
327,2315,1,2,,8139912,338,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
328,2315,1,2,,8139912,338,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
329,2315,1,2,,29215390,338,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
330,2315,1,2,,29215390,338,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
331,2326,1,1,,8139912,338,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
332,2380,1,2,,8139912,338,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
333,2391,1,1,,8139912,338,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
334,2417,1,1,,8139912,338,Inconclusive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
335,2435,1,2,,8139912,338,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
336,2445,1,2,,8139912,338,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
337,2451,1,2,,8139912,338,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
338,2451,1,2,,29215390,338,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
339,2462,1,1,,8139912,338,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
340,2462,1,1,,8139912,338,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
341,2472,1,2,,8139912,338,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
342,2472,1,2,,29215390,338,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
343,2517,2,1,,8139912,338,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
344,2517,2,1,,29215390,338,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
345,2520,1,4,,8139912,338,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
346,2521,1,3,,8139912,338,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
347,2523,1,1,,8139912,338,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
348,2524,1,2,,8139912,338,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
349,2528,1,2,,8139912,338,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
350,2528,1,2,,29215390,338,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
351,2540,1,2,,8139912,338,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
352,2544,1,2,,8139912,338,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
353,2546,1,1,,8139912,338,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
354,2546,1,1,,29215390,338,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
355,2549,1,1,,8139912,338,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
356,2549,1,1,,29215390,338,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
357,2550,1,3,,8139912,338,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
358,2551,1,1,,8139912,338,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
359,2551,1,1,,29215390,338,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
360,2553,1,2,,8139912,338,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
361,2557,1,3,,8139912,338,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
362,2563,1,1,,8139912,338,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
363,2599,1,2,,8139912,338,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
364,2606,1,2,,8139912,338,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
365,2629,1,1,,8139912,338,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
366,2642,1,2,,8139912,338,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
367,2648,1,2,,8139912,338,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
368,2650,2,1,,8139912,338,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
369,2661,1,1,,8139912,338,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
370,2662,2,1,,8139912,338,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
371,2674,1,1,,8139912,338,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
372,2675,1,1,,8139912,338,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
373,2676,1,2,,8139912,338,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
374,2685,1,1,,8139912,338,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
375,2690,1,2,,8139912,338,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
376,2706,1,1,,8139912,338,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
377,2716,1,1,,8139912,338,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
378,2717,1,2,,8139912,338,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
379,2718,1,1,,8139912,338,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
380,2732,1,1,,8139912,338,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
381,2751,2,2,,8139912,338,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
382,2796,1,4,,8139912,338,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
383,2797,1,2,,8139912,338,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
384,2805,2,2,,8139912,338,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
385,2806,2,2,,8139912,338,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
386,2825,1,2,,8139912,338,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
387,7596,3,3,,103164944,338,Unspecified,,,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),Other,10821711.0,
388,19262,5,1,,103164944,338,Unspecified,,,,,Aqueous solubility,Other,10866370.0,
389,19419,3,4,,103164944,338,Unspecified,,,,,Partition coefficient (logD7.4),Other,9544199.0,
390,20050,3,3,,103164944,338,Unspecified,,,,,Human absorption A (%),Other,9544199.0,
391,23251,3,3,,103164944,338,Unspecified,,,,,Partition coefficient (logP),Other,3599019.0,
392,23252,3,3,,103164944,338,Unspecified,,,,,Partition coefficient (logP) (benzene),Other,3599019.0,
393,23253,3,3,,103164944,338,Unspecified,,,,,Partition coefficient (logP) (carbon tetrachloride),Other,3599019.0,
394,23254,3,3,,103164944,338,Unspecified,,,,,Partition coefficient (logP) (chloroform),Other,3599019.0,
395,23255,3,3,,103164944,338,Unspecified,,,,,Partition coefficient (logP) (ether),Other,3599019.0,
396,23256,3,3,,103164944,338,Unspecified,,,,,Partition coefficient (logP) (hexane),Other,3599019.0,
397,24263,5,2,,103164944,338,Unspecified,,,,,"Ability to undergo in vitro ester hydrolysis in 80% human plasma ( pH of 7.4) at 37 degree Celsius expressed as half life of N,N-diethylglycolamide ester hydrolysis",Other,3820215.0,
398,24265,3,4,,103164944,338,Unspecified,,,,,Ability to undergo in vitro ester hydrolysis in 80% human plasma ( pH of 7.4) at 37 degree Celsius expressed as half life of methyl ester hydrolysis,Other,3820215.0,
399,25608,3,4,,103164944,338,Unspecified,,,,,Dissociation constant was determined at pH 7.2,Other,6802973.0,
400,25612,3,4,,103164944,338,Unspecified,,,,,Dissociation constant was determined spectrophotometrically; Experiment 1,Other,6802973.0,
401,25613,3,4,,103164944,338,Unspecified,,,,,Dissociation constant was determined spectrophotometrically; Experiment 2,Other,6802973.0,
402,26793,3,3,,103164944,338,Unspecified,,,,,Partition coefficient (logP),Other,6802973.0,
403,27167,3,4,,103164944,338,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
404,28681,3,4,,103164944,338,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
405,28921,3,3,,103164944,338,Unspecified,,,,,Partition coefficient (logP) (hexadecane),Other,11300874.0,
406,28926,3,3,,103164944,338,Unspecified,,,,,Effective permeability corrected for ionization,Other,11300874.0,
407,28928,3,3,,103164944,338,Unspecified,,,,,Intrinsic permeability of the compound,Other,11300874.0,
408,29359,3,3,,103164944,338,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
409,29811,4,3,,103164944,338,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
410,34782,9,2,,103164944,338,Unspecified,,,1000.0,IC50,In vitro inhibition of rabbit lens aldose reductase.,Confirmatory,3097317.0,
411,34786,4,7,,103164944,338,Unspecified,,,,,In vitro inhibition of rabbit lens aldose reductase at 10e-4 M.,Other,3097317.0,
412,34788,3,7,,103164944,338,Unspecified,,,,,In vitro inhibition of rabbit lens aldose reductase at 10e-5 M.,Other,3097317.0,
413,34789,3,7,,103164944,338,Unspecified,,,,,In vitro inhibition of rabbit lens aldose reductase at 10e-6 M.,Other,3097317.0,
414,38551,7,2,,103164944,338,Unspecified,,,1.8,Ki,Inhibitory activity against binding of [125I]IMSB to amyloid beta in brain,Confirmatory,11428920.0,
415,40626,5,2,,103164944,338,Unspecified,,,,,Inhibitory activity on germination of Bacillus subtilis PCI219 spores was determined; No inhibition at 5*10e-2 M,Other,6802973.0,
416,55746,3,3,,103164944,338,Unspecified,,,,,Inhibitory activity against family of dihydroorotate dehydrogenase 1A (1A DHOD) from Lactococcus lactis at 1 uMolar concentration,Other,11520193.0,
417,91481,4,7,,103164944,338,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
418,93781,6,2,,103164944,338,Unspecified,,,21000.0,IC50,Inhibitory activity against proteolytic release of C5a in activated human serum was determined,Confirmatory,12801233.0,
419,107292,3,3,,103164944,338,Inconclusive,,,,,"Compound was evaluated for its analgesic activity in mice by mouse phenylquinone writhing assay, and the activity relative to aspirin was reported; Not tested",Other,3097317.0,
420,170137,3,3,,103164944,338,Inconclusive,,,,,Compound was evaluated for its ability to reduce carrageenan induced inflammation of rat paw and activity relative to phenylbutazone was reported; Not tested,Other,3097317.0,
421,208331,9,2,,103164944,338,Unspecified,,,25000.0,Kd,Binding to stromelysin (MMP-3) in place of acetohydroxamic acid.,Confirmatory,12477346.0,
422,223690,7,1,,103164944,338,Unspecified,,,,,Inhibitory activity against protein tyrosine phosphatases (PTP1B) (Kis=slope inhibitory constant),Other,10649970.0,
423,237685,4,3,,103164944,338,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
424,243230,4,1,,103164944,338,Unspecified,113576.0,213.0,5888440000.0,Ki,Binding affinity towards human serum albumin,Confirmatory,15801837.0,
425,266760,6,1,,103164944,338,Unspecified,,,,,Permeability coefficient in silicon membrane using diffusion cells,Other,16789751.0,
426,266761,7,1,,103164944,338,Unspecified,,,,,Effective permeability coefficient in 100% silicon membrane,Other,16789751.0,
427,266762,6,1,,103164944,338,Unspecified,,,,,Effective permeability coefficient in 100% IPM membrane,Other,16789751.0,
428,266763,4,1,,103164944,338,Unspecified,,,,,Membrane retention in 70% silicon-30% IPM membrane,Other,16789751.0,
429,266764,3,3,,103164944,338,Unspecified,,,,,"Membrane permeability, CA(t)/CD(0) in 70% silicon-30% IPM membrane",Other,16789751.0,
430,266765,6,1,,103164944,338,Unspecified,,,,,Effective permeability coefficient in 70% silicon-30% IPM membrane,Other,16789751.0,
431,266766,3,3,,103164944,338,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,16789751.0,
432,266767,3,3,,103164944,338,Unspecified,,,,,Membrane retention in 100% silicon membrane,Other,16789751.0,
433,266768,3,3,,103164944,338,Unspecified,,,,,"Membrane permeability, CA(t)/CD(0) in 100% silicon membrane",Other,16789751.0,
434,266769,3,3,,103164944,338,Unspecified,,,,,Membrane retention in 100% IPM membrane,Other,16789751.0,
435,266770,3,3,,103164944,338,Unspecified,,,,,"Membrane permeability, CA(t)/CD(0) in 100% IPM membrane",Other,16789751.0,
436,266771,6,1,,103164944,338,Unspecified,,,,,Permeability in human skin,Other,16789751.0,
437,288184,9,1,,103164944,338,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA,Other,17418579.0,
438,288185,7,1,,103164944,338,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer,Other,17418579.0,
439,288192,3,4,,103164944,338,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17418579.0,
440,288193,3,4,,103164944,338,Unspecified,,,,,"Flux ionization constant, pKa of the membrane permeability coefficient of the compound",Other,17418579.0,
441,288194,3,5,,103164944,338,Unspecified,,,,,"Intrinsic artificial membrane permeability coefficient, log P0 of the compound",Other,17418579.0,
442,288209,3,3,,103164944,338,Unspecified,,,,,Antifungal activity against Aspergillus ficuum MTCC 8184 by serial dilution method,Other,17428669.0,
443,288210,3,3,,103164944,338,Unspecified,,,,,Antifungal activity against Aspergillus parasiticus MTCC 8189 by serial dilution method,Other,17428669.0,
444,293934,10,1,,103164944,338,Unspecified,,,33800.0,IC50,Inhibition of pieris rapae Phenoloxidase,Confirmatory,17258462.0,
445,302815,3,3,,103164944,338,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,17931865.0,
446,309363,3,3,,103164944,338,Unspecified,,,,,Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear oedema at 0.3 umol/cm^2 after 6 hrs,Other,17768049.0,
447,311367,3,6,,103164944,338,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
448,316997,3,4,,103164944,338,Unspecified,,,,,Chemical stability in aqueous buffer at pH 1 after 3 hrs,Other,18293898.0,
449,316998,3,4,,103164944,338,Unspecified,,,,,Chemical stability in aqueous buffer at pH 7.4 after 3 hrs,Other,18293898.0,
450,331291,9,5,,103164944,338,Active,115449.0,759.0,9.92,Ki,Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydrase assay,Confirmatory,18501600.0,
451,331292,9,5,,103164944,338,Active,115456.0,760.0,7.12,Ki,Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay,Confirmatory,18501600.0,
452,331293,9,5,,103164944,338,Active,30580362.0,80733.0,7.2,Ki,Inhibition of mouse recombinant carbonic anhydrase 15 by stopped-flow CO2 hydrase assay,Confirmatory,18501600.0,
453,332455,5,9,,103164944,338,Unspecified,6686057.0,,,,Inhibition of mushroom tyrosinase assessed as oxidation of L-DOPA at 0.8 mM,Other,8021657.0,
454,332456,8,1,,103164944,338,Unspecified,6686057.0,,3900.0,ID50,Inhibition of mushroom tyrosinase assessed as oxidation of L-DOPA,Confirmatory,8021657.0,
455,332912,9,1,,103164944,338,Unspecified,,,,,Antimicrobial activity Propionibacterium acnes ATCC 11827 after 2 days by broth dilution method,Other,8158169.0,
456,342475,9,5,,103164944,338,Active,115449.0,759.0,9.9,Ki,Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
457,342476,9,5,,103164944,338,Active,115456.0,760.0,7.1,Ki,Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
458,342477,9,5,,103164944,338,Unspecified,134047703.0,761.0,885.0,Ki,Inhibition of human carbonic anhydrase 3 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
459,342478,9,5,,103164944,338,Active,115465.0,762.0,11.1,Ki,Inhibition of human carbonic anhydrase 4 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
460,342479,9,5,,103164944,338,Unspecified,461680.0,763.0,678.0,Ki,Inhibition of human carbonic anhydrase 5A by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
461,342480,9,5,,103164944,338,Unspecified,8928041.0,11238.0,355.0,Ki,Inhibition of human carbonic anhydrase 5B by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
462,342481,9,5,,103164944,338,Active,116241278.0,765.0,11.9,Ki,Inhibition of human carbonic anhydrase 6 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
463,342482,9,5,,103164944,338,Unspecified,1168744.0,766.0,82.1,Ki,Inhibition of human carbonic anhydrase 7 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
464,342483,9,5,,103164944,338,Unspecified,83300925.0,768.0,78.7,Ki,Inhibition of human carbonic anhydrase 9 catalytic domain by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
465,342484,9,5,,103164944,338,Active,5915866.0,771.0,8.8,Ki,Inhibition of human carbonic anhydrase 12 catalytic domain by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
466,342485,9,5,,103164944,338,Active,8928036.0,23632.0,49.8,Ki,Inhibition of human carbonic anhydrase 14 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
467,342486,9,5,,103164944,338,Unspecified,30580372.0,71934.0,67.0,Ki,Inhibition of mouse carbonic anhydrase 13 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
468,349140,11,2,,103164944,338,Unspecified,115449.0,759.0,560.0,IC50,Inhibition of human carbonic anhydrase 1 esterase activity by spectrophotometry,Confirmatory,18819808.0,
469,349141,11,2,,103164944,338,Unspecified,115456.0,760.0,680.0,IC50,Inhibition of human carbonic anhydrase 2 esterase activity by spectrophotometry,Confirmatory,18819808.0,
470,349142,11,2,,103164944,338,Unspecified,115449.0,759.0,620.0,Ki,Inhibition of human carbonic anhydrase 1 esterase activity by noncompetitive Lineweaver-Burke plot,Confirmatory,18819808.0,
471,349145,11,2,,103164944,338,Unspecified,115456.0,760.0,740.0,Ki,Inhibition of human carbonic anhydrase 2 esterase activity by non-competitive Lineweaver-Burke plot,Confirmatory,18819808.0,
472,360149,11,2,,103164944,338,Active,56404586.0,381203.0,43.6516,Ki,Inhibition of mouse Oat6-mediated [3H]ES uptake in Xenopus oocytes after 1 hr,Confirmatory,17553798.0,
473,360150,11,2,,103164944,338,Unspecified,81901833.0,18399.0,144.54399999999998,Ki,Inhibition of mouse Oat1-mediated [3H]PAH uptake in Xenopus oocytes after 1 hr,Confirmatory,17553798.0,
474,360151,3,4,,103164944,338,Unspecified,,,,,Ratio of pKi for mouse Oat1 expressed in Xenopus oocytes to pKi for mouse Oat6 expressed in Xenopus oocytes,Other,17553798.0,
475,369248,3,3,,103164944,338,Unspecified,,,,,Increase in ompX-lacZ expression in Escherichia coli deltaompX mutant assessed as ompX upregulation after 60 mins relative to control,Other,17606680.0,
476,369250,3,3,,103164944,338,Active,,,,,Increase in ompX-lacZ expression in Escherichia coli JM109 assessed as ompX upregulation after 60 mins relative to control,Other,17606680.0,
477,369251,3,3,,103164944,338,Active,,,,,Increase in ompX-lacZ expression in Escherichia coli JM109 assessed as increase in beta-galactosidase activity after 60 mins relative to control,Other,17606680.0,
478,369252,3,3,,103164944,338,Active,,,,,Increase in ompX-lacZ expression in Enterobacter aerogenes ATCC 15038 assessed as ompX upregulation after 60 mins relative to control,Other,17606680.0,
479,369253,3,3,,103164944,338,Active,,,,,Increase in ompX-lacZ expression in Enterobacter aerogenes ATCC 15038 assessed as increase in beta-galactosidase activity after 60 mins relative to control,Other,17606680.0,
480,369255,3,3,,103164944,338,Active,,,,,Induction of ompX-lacZ expression in Enterobacter aerogenes ATCC 15038 assessed as total RNA content after 30 mins by RT-PCR,Other,17606680.0,
481,369256,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion transcription in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control,Other,17606680.0,
482,369257,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion transcription in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control,Other,17606680.0,
483,369258,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion transcription in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control,Other,17606680.0,
484,369259,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion transcription in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control,Other,17606680.0,
485,369260,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion transcription in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control,Other,17606680.0,
486,369261,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion transcription in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control,Other,17606680.0,
487,369262,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion transcription in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control,Other,17606680.0,
488,369263,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion transcription in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control,Other,17606680.0,
489,369264,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion transcription in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control,Other,17606680.0,
490,369265,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion transcription in marA-negative Escherichia coli CH164 mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control,Other,17606680.0,
491,369266,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion transcription in marA-negative Escherichia coli CH164 mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control,Other,17606680.0,
492,369418,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion translation in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control,Other,17606680.0,
493,369613,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion translation in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control,Other,17606680.0,
494,369614,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion translation in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control,Other,17606680.0,
495,369615,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion translation in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control,Other,17606680.0,
496,369616,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion translation in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control,Other,17606680.0,
497,369617,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion translation in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control,Other,17606680.0,
498,369618,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion translation in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control,Other,17606680.0,
499,369619,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion translation in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control,Other,17606680.0,
500,369620,3,3,,103164944,338,Unspecified,,,,,Effect on ompF-lacZ fusion translation in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control,Other,17606680.0,
501,369624,3,3,,103164944,338,Unspecified,,,,,Induction of ompX transcription in marA-positive Escherichia coli K12 relative to control,Other,17606680.0,
502,384955,4,4,,103164944,338,Unspecified,,,,,Intrinsic aqueous solubility at pH 10 by shake-flask method,Other,18396854.0,
503,385427,3,3,,103164944,338,Unspecified,,,,,Inhibition of soybean 15-lipoxygenase,Other,18314336.0,
504,397153,11,1,,103164944,338,Inactive,,,,,Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL preincubated for 1 hr before Cu2+ challenge,Other,11325231.0,
505,401415,13,2,,103164944,338,Unspecified,130224.0,281987.0,,IC50,Inhibition of bovine brain PI-PLCgamma1,Confirmatory,9677265.0,
506,409741,3,7,,103164944,338,Unspecified,,,,,Inhibition of PTP1B expressed in Escherichia coli,Other,18722777.0,
507,434955,1,2,,8139912,338,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
508,434962,1,2,,8139912,338,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
509,434973,1,3,,8139912,338,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
510,434989,1,1,,8139912,338,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
511,435003,1,3,,8139912,338,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
512,435005,1,1,,8139912,338,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
513,435022,2,2,,8139912,338,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
514,435030,1,2,,8139912,338,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
515,435030,1,2,,8139912,338,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
516,436417,3,3,,103164944,338,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed as ulcer index at 2290 mg/kg, po by Rainsford's cold stress method",Other,19442419.0,
517,447578,3,4,,103164944,338,Unspecified,2498443.0,3065.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
518,447578,3,4,,103164944,338,Unspecified,3334210.0,8841.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
519,447578,3,4,,103164944,338,Unspecified,19865267.0,9734.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
520,447578,3,4,,103164944,338,Unspecified,26394832.0,79885.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
521,447578,3,4,,103164944,338,Unspecified,27734403.0,83933.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
522,447578,3,4,,103164944,338,Unspecified,29839394.0,55869.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
523,447578,3,4,,103164944,338,Unspecified,30913097.0,51564.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
524,447578,3,4,,103164944,338,Unspecified,68068066.0,3066.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
525,447578,3,4,,103164944,338,Unspecified,205371758.0,10013.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
526,447578,3,4,,103164944,338,Unspecified,259016348.0,9759.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
527,447578,3,4,,103164944,338,Unspecified,296434519.0,10014.0,,,Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay,Other,19520580.0,
528,449283,3,4,,103164944,338,Inactive,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production at 10 ug/ml treated for 1 hr before LPS challenge measured after 24 hrs by Griess reagent method,Other,19666224.0,
529,449728,1,2,,8139912,338,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
530,449739,1,2,,8139912,338,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
531,449762,1,2,,8139912,338,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
532,449763,1,3,,8139912,338,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
533,449768,1,1,,8139912,338,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
534,454616,3,4,,103164944,338,Inconclusive,,,,,Antioxidant activity assessed as DPPH radical scavenging activity at 10 uM,Other,20005707.0,
535,454617,4,3,,103164944,338,Unspecified,,,,,Inhibition of trypsin at 10 uM,Other,20005707.0,
536,454618,4,8,,103164944,338,Inconclusive,3914304.0,443460.0,,,Inhibition of ovine COX2 at 1 mM by colorimetric assay,Other,20005707.0,
537,454619,4,6,,103164944,338,Unspecified,,,,,Inhibition of beta-glucuronidase at 10 uM,Other,20005707.0,
538,455986,3,5,,103164944,338,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
539,460784,8,1,,103164944,338,Unspecified,,,,IC50,Inhibition of IKK-beta by tome resolved fluorescence assay,Confirmatory,20044255.0,
540,463073,1,2,,8139912,338,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
541,463075,1,1,,8139912,338,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
542,463079,1,2,,8139912,338,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
543,463082,1,1,,8139912,338,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
544,463104,1,2,,8139912,338,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
545,463111,1,1,,8139912,338,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
546,463115,1,1,,8139912,338,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
547,463141,1,2,,8139912,338,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
548,463165,1,1,,8139912,338,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
549,463187,1,1,,8139912,338,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
550,463190,1,2,,8139912,338,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
551,463193,1,1,,8139912,338,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
552,463195,1,2,,8139912,338,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
553,463210,1,2,,8139912,338,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
554,463212,1,1,,8139912,338,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
555,463254,1,1,,8139912,338,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
556,467611,3,6,,103164944,338,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
557,467612,3,6,,103164944,338,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
558,467613,5,3,,103164944,338,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
559,475504,3,3,,103164944,338,Active,,,,,Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins,Other,19640715.0,
560,475505,3,3,,103164944,338,Active,,,,,Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins,Other,19640715.0,
561,476929,3,3,,103164944,338,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
562,481439,3,4,,103164944,338,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
563,481440,3,4,,103164944,338,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,20373811.0,
564,481441,3,6,,103164944,338,Unspecified,,,,,Aqueous diffusivity at 37C,Other,20373811.0,
565,481442,3,6,,103164944,338,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
566,481444,3,4,,103164944,338,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20373811.0,
567,481446,5,1,,103164944,338,Unspecified,,,,,Effective permeability across human jejunum,Other,20373811.0,
568,485270,1,1,,8139912,338,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
569,485272,1,1,,8139912,338,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
570,485273,2,1,,8139912,338,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
571,485275,1,3,,8139912,338,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
572,485281,1,1,,8139912,338,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
573,485281,1,1,,29215390,338,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
574,485290,1,1,,8139912,338,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
575,485290,1,1,,29215390,338,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
576,485294,1,1,,8139912,338,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
577,485297,1,1,,8139912,338,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
578,485298,1,1,,8139912,338,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
579,485313,1,2,,8139912,338,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
580,485314,1,1,,8139912,338,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
581,485317,1,2,,8139912,338,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
582,485341,1,1,,8139912,338,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
583,485344,1,1,,8139912,338,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
584,485346,1,1,,8139912,338,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
585,485346,1,1,,8139912,338,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
586,485347,1,2,,8139912,338,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
587,485349,1,1,,8139912,338,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
588,485353,2,1,,8139912,338,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
589,485358,1,1,,8139912,338,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
590,485360,1,1,,8139912,338,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
591,485364,1,1,,8139912,338,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
592,485367,1,2,,8139912,338,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
593,488806,1,2,,8139912,338,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
594,488837,1,1,,8139912,338,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
595,488839,1,1,,8139912,338,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
596,488839,1,1,,8139912,338,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
597,488847,1,3,,8139912,338,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
598,488862,1,1,,8139912,338,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
599,488890,1,2,,8139912,338,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
600,488895,1,2,,8139912,338,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
601,488896,1,1,,8139912,338,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
602,488899,1,1,,8139912,338,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
603,488922,1,2,,8139912,338,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
604,488965,1,2,,8139912,338,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
605,488966,1,1,,8139912,338,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
606,488975,1,2,,8139912,338,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
607,488977,1,2,,8139912,338,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
608,489030,2,1,,8139912,338,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
609,489031,2,1,,8139912,338,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
610,492947,1,1,,8139912,338,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
611,492953,1,1,,8139912,338,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
612,492956,1,1,,8139912,338,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
613,492972,1,1,,8139912,338,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
614,493005,1,1,,8139912,338,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
615,493008,1,1,,8139912,338,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
616,493008,1,1,,8139912,338,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
617,493008,1,1,,8139912,338,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
618,493008,1,1,,8139912,338,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
619,493011,1,1,,8139912,338,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
620,493012,1,1,,8139912,338,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
621,493014,1,1,,8139912,338,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
622,493027,1,2,,8139912,338,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
623,493027,1,2,,8139912,338,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
624,493035,1,2,,8139912,338,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
625,493035,1,2,,8139912,338,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
626,493036,1,2,,8139912,338,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
627,493056,1,1,,8139912,338,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
628,493084,1,1,,8139912,338,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
629,493087,1,1,,8139912,338,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
630,493091,1,1,,8139912,338,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
631,493098,1,1,,8139912,338,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
632,493131,1,1,,8139912,338,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
633,493160,1,1,,8139912,338,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
634,493187,1,2,,8139912,338,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
635,493244,1,1,,8139912,338,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
636,493244,1,1,,8139912,338,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
637,493244,1,1,,8139912,338,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
638,493244,1,1,,8139912,338,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
639,504326,1,2,,8139912,338,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
640,504326,1,2,,8139912,338,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
641,504327,1,1,,8139912,338,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
642,504327,1,1,,29215390,338,Inconclusive,153791535.0,2648.0,11.2202,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
643,504329,1,1,,8139912,338,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
644,504332,1,1,,8139912,338,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
645,504332,1,1,,29215390,338,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
646,504333,1,1,,8139912,338,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
647,504339,1,1,,8139912,338,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
648,504357,1,1,,8139912,338,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
649,504357,1,1,,8139912,338,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
650,504406,1,1,,8139912,338,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
651,504408,2,1,,8139912,338,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
652,504411,1,1,,8139912,338,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
653,504414,1,1,,8139912,338,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
654,504414,1,1,,8139912,338,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
655,504423,1,1,,8139912,338,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
656,504441,1,1,,8139912,338,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
657,504444,1,1,,8139912,338,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
658,504454,1,3,,8139912,338,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
659,504462,1,1,,8139912,338,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
660,504466,1,1,,8139912,338,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
661,504467,1,1,,8139912,338,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
662,504490,1,2,,8139912,338,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
663,504523,1,1,,8139912,338,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
664,504523,1,1,,8139912,338,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
665,504541,1,1,,8139912,338,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
666,504558,1,1,,8139912,338,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
667,504577,2,2,,8139912,338,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
668,504582,2,1,,8139912,338,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
669,504594,1,1,,8139912,338,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
670,504600,1,2,,8139912,338,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
671,504621,1,1,,8139912,338,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
672,504634,1,1,,8139912,338,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
673,504648,1,1,,8139912,338,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
674,504651,1,1,,8139912,338,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
675,504652,1,1,,8139912,338,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
676,504660,1,1,,8139912,338,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
677,504690,1,3,,8139912,338,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
678,504692,2,2,,8139912,338,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
679,504700,1,1,,8139912,338,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
680,504700,1,1,,8139912,338,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
681,504706,1,1,,8139912,338,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
682,504707,1,1,,8139912,338,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
683,504707,1,1,,8139912,338,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
684,504720,1,1,,8139912,338,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
685,504734,1,1,,8139912,338,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
686,504766,2,1,,8139912,338,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
687,504775,1,1,,8139912,338,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
688,504803,1,1,,8139912,338,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
689,504810,1,2,,8139912,338,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
690,504812,1,2,,8139912,338,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
691,504832,1,1,,8139912,338,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
692,504834,1,1,,8139912,338,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
693,504842,1,1,,8139912,338,Inconclusive,4090929.0,10576.0,70.7946,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
694,504845,1,1,,8139912,338,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
695,504847,1,1,,8139912,338,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
696,504847,1,1,,29215390,338,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
697,504884,1,2,,8139912,338,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
698,504891,1,1,,8139912,338,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
699,504894,1,1,,8139912,338,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
700,504937,1,2,,8139912,338,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
701,515780,5,1,,103164944,338,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
702,540253,1,1,,8139912,338,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
703,540253,1,1,,8139912,338,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
704,540253,1,1,,8139912,338,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
705,540256,1,2,,8139912,338,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
706,540263,1,1,,8139912,338,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
707,540263,1,1,,8139912,338,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
708,540267,1,1,,8139912,338,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
709,540275,1,1,,8139912,338,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
710,540276,1,2,,8139912,338,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
711,540276,1,2,,26754507,338,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
712,540276,1,2,,29215390,338,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
713,540277,1,1,,8139912,338,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
714,540295,1,1,,8139912,338,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
715,540303,1,1,,8139912,338,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
716,540303,1,1,,8139912,338,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
717,540303,1,1,,8139912,338,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
718,540308,1,1,,8139912,338,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
719,540317,1,1,,8139912,338,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
720,540336,1,1,,8139912,338,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
721,540336,1,1,,8139912,338,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
722,540364,1,2,,8139912,338,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
723,555340,2,3,,103164944,338,Inconclusive,,,,,Effect on growth in Staphylococcus aureus MN8 at 0.50 % after 24 hrs (Rvb = 100%),Other,19223628.0,
724,555341,2,3,,103164944,338,Unspecified,,,,,Effect on growth in Staphylococcus aureus MN8 at 0.10 % after 24 hrs (Rvb = 100%),Other,19223628.0,
725,555372,3,3,,103164944,338,Inconclusive,,,,,Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 0.50 % after 24 hrs relative to control,Other,19223628.0,
726,555373,2,3,,103164944,338,Unspecified,,,,,Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 0.10 % after 24 hrs relative to control,Other,19223628.0,
727,566699,3,7,,103164944,338,Unspecified,6686057.0,,,,Inhibition of mushroom tyrosinase at 1 mM after 10 mins,Other,21189019.0,
728,566700,3,7,,103164944,338,Unspecified,126407.0,240.0,,,Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay,Other,21189019.0,
729,566701,3,8,,103164944,338,Unspecified,50402185.0,,,,Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay,Other,21189019.0,
730,566702,2,9,,103164944,338,Unspecified,116852.0,4312.0,,,Inhibition of human recombinant MMP1 at 1 mM after 30 mins,Other,21189019.0,
731,566703,3,7,,103164944,338,Unspecified,116856.0,4313.0,,,Inhibition of human recombinant MMP2 at 1 mM after 30 mins,Other,21189019.0,
732,566704,2,9,,103164944,338,Unspecified,116857.0,4314.0,,,Inhibition of human recombinant MMP3 at 1 mM after 30 mins,Other,21189019.0,
733,566705,3,7,,103164944,338,Unspecified,116862.0,4317.0,,,Inhibition of human recombinant MMP8 at 1 mM after 30 mins,Other,21189019.0,
734,566706,3,7,,103164944,338,Unspecified,269849668.0,4318.0,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,Other,21189019.0,
735,566707,3,7,,103164944,338,Unspecified,266649.0,18126.0,,,Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay,Other,21189019.0,
736,566711,8,4,,103164944,338,Unspecified,6686057.0,,100.0,IC50,Inhibition of mushroom tyrosinase after 10 mins,Confirmatory,21189019.0,
737,588211,2,3,,103164944,338,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
738,588212,2,3,,103164944,338,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
739,588213,2,3,,103164944,338,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
740,588334,1,1,,8139912,338,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
741,588335,1,1,,8139912,338,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
742,588342,1,1,,8139912,338,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
743,588352,1,2,,8139912,338,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
744,588354,1,1,,8139912,338,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
745,588358,1,2,,8139912,338,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
746,588368,1,2,,8139912,338,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
747,588391,1,1,,8139912,338,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
748,588405,1,1,,8139912,338,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
749,588413,1,2,,8139912,338,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
750,588436,1,1,,8139912,338,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
751,588453,1,1,,8139912,338,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
752,588456,1,1,,8139912,338,Inactive,8659577.0,58819.0,63.0957,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
753,588458,1,1,,8139912,338,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
754,588459,1,2,,8139912,338,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
755,588459,1,2,,8139912,338,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
756,588459,1,2,,8139912,338,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
757,588460,1,2,,8139912,338,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
758,588460,1,2,,8139912,338,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
759,588460,1,2,,8139912,338,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
760,588461,1,2,,8139912,338,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
761,588461,1,2,,8139912,338,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
762,588461,1,2,,8139912,338,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
763,588473,1,1,,8139912,338,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
764,588473,1,1,,8139912,338,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
765,588475,1,2,,8139912,338,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
766,588475,1,2,,8139912,338,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
767,588478,1,2,,124800348,338,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
768,588489,1,1,,8139912,338,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
769,588492,1,1,,8139912,338,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
770,588493,1,2,,8139912,338,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
771,588497,1,2,,8139912,338,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
772,588497,1,2,,8139912,338,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
773,588497,1,2,,8139912,338,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
774,588499,1,3,,8139912,338,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
775,588499,1,3,,8139912,338,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
776,588499,1,3,,8139912,338,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
777,588501,1,2,,8139912,338,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
778,588501,1,2,,8139912,338,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
779,588501,1,2,,8139912,338,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
780,588506,1,2,,8139912,338,Active,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
781,588511,1,2,,8139912,338,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
782,588549,1,1,,8139912,338,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
783,588550,1,1,,8139912,338,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
784,588579,1,1,,8139912,338,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
785,588579,1,1,,29215390,338,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
786,588590,1,1,,8139912,338,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
787,588591,1,1,,8139912,338,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
788,588621,1,1,,8139912,338,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
789,588627,1,1,,8139912,338,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
790,588664,1,2,,8139912,338,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
791,588664,1,2,,8139912,338,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
792,588674,1,2,,8139912,338,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
793,588675,1,1,,8139912,338,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
794,588676,1,1,,8139912,338,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
795,588685,1,1,,8139912,338,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
796,588689,1,1,,8139912,338,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
797,588692,2,1,,8139912,338,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
798,588726,1,2,,8139912,338,Active,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
799,588727,1,1,,8139912,338,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
800,588795,1,1,,8139912,338,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
801,588814,1,3,,8139912,338,Active,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
802,588819,1,4,,8139912,338,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
803,588850,1,1,,8139912,338,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
804,588852,1,3,,8139912,338,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
805,588855,1,1,,8139912,338,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
806,588856,1,1,,8139912,338,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
807,589074,1,10,,103164944,338,Unspecified,29839451.0,54600.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A9,Other,,
808,602123,1,1,,8139912,338,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
809,602141,1,1,,8139912,338,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
810,602162,1,1,,8139912,338,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
811,602163,1,1,,8139912,338,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
812,602179,1,2,,8139912,338,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
813,602229,1,1,,8139912,338,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
814,602233,1,1,,8139912,338,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
815,602244,1,2,,8139912,338,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
816,602247,1,2,,8139912,338,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
817,602248,1,2,,8139912,338,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
818,602250,1,2,,8139912,338,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
819,602252,1,1,,8139912,338,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
820,602252,1,1,,8139912,338,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
821,602261,1,1,,8139912,338,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
822,602274,1,2,,8139912,338,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
823,602281,1,1,,8139912,338,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
824,602281,1,1,,8139912,338,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
825,602310,1,2,,8139912,338,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
826,602313,1,1,,8139912,338,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
827,602329,1,1,,8139912,338,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
828,602332,1,1,,8139912,338,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
829,602332,1,1,,29215390,338,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
830,602332,1,1,,124892197,338,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
831,602340,1,2,,8139912,338,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
832,602342,2,1,,8139912,338,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
833,602346,1,1,,8139912,338,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
834,602363,1,1,,8139912,338,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
835,602393,1,1,,8139912,338,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
836,602396,1,2,,8139912,338,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
837,602399,1,2,,8139912,338,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
838,602405,1,1,,8139912,338,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
839,602410,1,1,,8139912,338,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
840,602429,1,1,,8139912,338,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
841,602438,1,1,,8139912,338,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
842,602440,1,1,,8139912,338,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
843,602449,1,2,,8139912,338,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
844,602481,1,1,,8139912,338,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
845,603953,1,3,,103164944,338,Unspecified,,,,,"In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat",Other,17544548.0,
846,604020,1,4,,103164944,338,Active,,,,,Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
847,604021,3,1,,103164944,338,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
848,604022,1,4,,103164944,338,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
849,604023,1,3,,103164944,338,Unspecified,,,,,Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
850,604024,1,3,,103164944,338,Unspecified,,,,,Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr,Other,19764786.0,
851,604025,1,4,,103164944,338,Unspecified,,,,,Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
852,604026,1,4,,103164944,338,Unspecified,,,,,Unbound CSF to plasma concentration ratio in human,Other,19764786.0,
853,604741,1,9,,103164944,338,Unspecified,113576.0,213.0,,,Displacement of radiolabeled warfarin from fatty acid-free human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
854,604742,1,9,,103164944,338,Unspecified,113576.0,213.0,,,Displacement of radiolabeled dansylsarcosine from fatty acid-free human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
855,604743,1,9,,103164944,338,Unspecified,113576.0,213.0,,,Displacement of radiolabeled warfarin from fatty acid containing human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
856,604744,1,9,,103164944,338,Unspecified,113576.0,213.0,,,Displacement of radiolabeled dansylsarcosine from fatty acid containing human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
857,607496,6,5,,103164944,338,Unspecified,116241278.0,765.0,2320.0,Ki,Inhibition of human CA6 using 4-nitrophenylacetate substrate by esterase assay,Confirmatory,21669522.0,
858,607497,6,5,,103164944,338,Unspecified,123910379.0,,324.0,Ki,Inhibition of Dicentrarchus labrax CA using 4-nitrophenylacetate substrate by esterase assay,Confirmatory,21669522.0,
859,619728,1,4,,103164944,338,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at dose equimolar to 120 mg/kg aspirin, administered intragastrically immediately after carrageenan challenge measured after 3 hrs by water plethysmometer relative to control",Other,21906954.0,
860,619730,1,4,,103164944,338,Unspecified,,,,,"Ulcerogenicity in Wistar rat assessed as damage in gastric mucosa-lesion index at dose equimolar to 120 mg/kg aspirin, administered intragastrically after 3 hrs by stereomicroscopy",Other,21906954.0,
861,623870,1,1,,8139912,338,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
862,623870,1,1,,8139912,338,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
863,623877,1,1,,8139912,338,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
864,623901,1,1,,8139912,338,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
865,624030,1,2,,124892197,338,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
866,624037,1,3,,8139912,338,Active,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
867,624038,1,3,,8139912,338,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
868,624040,1,3,,8139912,338,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
869,624125,1,4,,8139912,338,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
870,624126,1,3,,8139912,338,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
871,624127,1,2,,8139912,338,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
872,624168,1,1,,8139912,338,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
873,624169,1,1,,8139912,338,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
874,624170,1,1,,8139912,338,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
875,624170,1,1,,124892197,338,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
876,624171,1,1,,8139912,338,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
877,624172,1,1,,8139912,338,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
878,624172,1,1,,124892197,338,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
879,624173,1,3,,8139912,338,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
880,624173,1,3,,124892197,338,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
881,624178,1,1,,8139912,338,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
882,624202,1,1,,8139912,338,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
883,624204,1,2,,8139912,338,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
884,624246,1,1,,8139912,338,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
885,624256,1,2,,8139912,338,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
886,624263,1,1,,8139912,338,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
887,624263,1,1,,8139912,338,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
888,624267,1,2,,8139912,338,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
889,624267,1,2,,8139912,338,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
890,624268,1,3,,8139912,338,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
891,624288,1,1,,8139912,338,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
892,624296,1,1,,8139912,338,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
893,624297,1,1,,8139912,338,Inconclusive,7705682.0,51053.0,1.9953,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
894,624304,1,2,,8139912,338,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
895,624330,1,2,,8139912,338,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
896,624352,1,1,,8139912,338,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
897,624354,1,1,,8139912,338,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
898,624377,1,1,,8139912,338,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
899,624414,1,1,,8139912,338,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
900,624415,1,2,,8139912,338,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
901,624416,1,1,,8139912,338,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
902,624417,1,1,,8139912,338,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
903,624418,1,1,,8139912,338,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
904,624463,1,1,,8139912,338,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
905,624464,1,1,,8139912,338,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
906,624465,1,1,,8139912,338,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
907,624466,1,3,,8139912,338,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
908,624467,1,1,,8139912,338,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
909,624483,1,1,,8139912,338,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
910,624615,1,8,,103164944,338,Unspecified,549155.0,7365.0,,,Specific activity of expressed human recombinant UGT2B10,Other,10836148.0,
911,624618,3,2,,103164944,338,Unspecified,6175083.0,7363.0,,,Specific activity of expressed human recombinant UGT2B4,Other,10836148.0,
912,625144,5,5,,103164944,338,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
913,625145,4,7,,103164944,338,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
914,625146,5,5,,103164944,338,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
915,625147,4,7,,103164944,338,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
916,625148,4,7,,103164944,338,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
917,625149,4,7,,103164944,338,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
918,625150,5,5,,103164944,338,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
919,625151,4,7,,103164944,338,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
920,625152,4,7,,103164944,338,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
921,625153,4,7,,103164944,338,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
922,625154,4,7,,103164944,338,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
923,625155,4,7,,103164944,338,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
924,625156,1,9,,103164944,338,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
925,625157,6,2,,103164944,338,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
926,625158,3,4,,103164944,338,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
927,625159,5,5,,103164944,338,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
928,625160,1,9,,103164944,338,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
929,625161,4,7,,103164944,338,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
930,625162,4,7,,103164944,338,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
931,625163,4,7,,103164944,338,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
932,625164,1,6,,103164944,338,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
933,625165,3,4,,103164944,338,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
934,625166,3,4,,103164944,338,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
935,625167,5,5,,103164944,338,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
936,625168,4,7,,103164944,338,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
937,625169,1,6,,103164944,338,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
938,625170,3,4,,103164944,338,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
939,625171,4,7,,103164944,338,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
940,625172,4,7,,103164944,338,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
941,625173,5,5,,103164944,338,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
942,625174,5,5,,103164944,338,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
943,625175,5,5,,103164944,338,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
944,625176,1,9,,103164944,338,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
945,625177,5,5,,103164944,338,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
946,625178,5,5,,103164944,338,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
947,625179,1,9,,103164944,338,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
948,625180,5,5,,103164944,338,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
949,625181,5,5,,103164944,338,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
950,625182,5,5,,103164944,338,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
951,625183,5,5,,103164944,338,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
952,625184,5,5,,103164944,338,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
953,625185,5,5,,103164944,338,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
954,625186,5,5,,103164944,338,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
955,625187,5,5,,103164944,338,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
956,625188,1,9,,103164944,338,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
957,625189,1,7,,103164944,338,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
958,625190,4,5,,103164944,338,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
959,625191,4,7,,103164944,338,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
960,625192,4,7,,103164944,338,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
961,625193,5,5,,103164944,338,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
962,625194,4,7,,103164944,338,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
963,625195,4,7,,103164944,338,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
964,625196,5,6,,103164944,338,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
965,625197,3,4,,103164944,338,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
966,625198,4,7,,103164944,338,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
967,625199,4,7,,103164944,338,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
968,625200,4,7,,103164944,338,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
969,625201,4,7,,103164944,338,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
970,625202,4,7,,103164944,338,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
971,625203,4,7,,103164944,338,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
972,625204,4,7,,103164944,338,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
973,625205,4,7,,103164944,338,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
974,625206,4,7,,103164944,338,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
975,625207,4,7,,103164944,338,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
976,625208,5,5,,103164944,338,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
977,625209,4,7,,103164944,338,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
978,625210,3,4,,103164944,338,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
979,625211,1,6,,103164944,338,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
980,625212,3,4,,103164944,338,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
981,625213,4,7,,103164944,338,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
982,625214,1,9,,103164944,338,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
983,625215,3,4,,103164944,338,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
984,625216,3,4,,103164944,338,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
985,625217,4,7,,103164944,338,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
986,625218,4,7,,103164944,338,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
987,625219,3,4,,103164944,338,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
988,625220,4,7,,103164944,338,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
989,625221,4,7,,103164944,338,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
990,625222,4,7,,103164944,338,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
991,625223,4,7,,103164944,338,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
992,625224,3,4,,103164944,338,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
993,625225,3,4,,103164944,338,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
994,625226,4,7,,103164944,338,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
995,625227,4,7,,103164944,338,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
996,625228,4,7,,103164944,338,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
997,625229,5,5,,103164944,338,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
998,625230,1,6,,103164944,338,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
999,625231,4,7,,103164944,338,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1000,625232,1,9,,103164944,338,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1001,625233,4,7,,103164944,338,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1002,625234,3,4,,103164944,338,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1003,625235,4,7,,103164944,338,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1004,625236,5,5,,103164944,338,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1005,625237,4,7,,103164944,338,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1006,625238,4,7,,103164944,338,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1007,625239,4,7,,103164944,338,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1008,625240,1,9,,103164944,338,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1009,625241,4,7,,103164944,338,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1010,625242,4,7,,103164944,338,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1011,625243,5,5,,103164944,338,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1012,625244,5,5,,103164944,338,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1013,625245,5,5,,103164944,338,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1014,625246,1,9,,103164944,338,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1015,625247,5,5,,103164944,338,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1016,625248,5,5,,103164944,338,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1017,625249,5,5,,103164944,338,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1018,625250,5,5,,103164944,338,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1019,625251,5,5,,103164944,338,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1020,625252,4,7,,103164944,338,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1021,625253,4,7,,103164944,338,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1022,625254,4,7,,103164944,338,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1023,625255,4,7,,103164944,338,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1024,625256,4,7,,103164944,338,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1025,625257,4,7,,103164944,338,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1026,625258,4,7,,103164944,338,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1027,625259,4,7,,103164944,338,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1028,625260,3,4,,103164944,338,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1029,625261,3,4,,103164944,338,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1030,625262,3,4,,103164944,338,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1031,625263,4,7,,103164944,338,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1032,625264,3,4,,103164944,338,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1033,625265,1,6,,103164944,338,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1034,625266,3,4,,103164944,338,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1035,625267,3,4,,103164944,338,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1036,625268,4,2,,103164944,338,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1037,625268,4,2,,103164944,338,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1038,625268,4,2,,103164944,338,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1039,625268,4,2,,103164944,338,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1040,625269,4,7,,103164944,338,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1041,625270,4,7,,103164944,338,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1042,625271,5,5,,103164944,338,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1043,625272,3,4,,103164944,338,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1044,625273,4,6,,103164944,338,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1045,625274,1,6,,103164944,338,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1046,625275,3,4,,103164944,338,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1047,631927,3,2,,103164944,338,Active,,,0.2,IC50,Antihemorrhagic activity in ddY mouse assessed as inhibition of Protobothrops flavoviridis venom-induced hemorrhagic lesion formation compound incubated with venom for 10 mins and administered subcutaneously measured after 24 hrs,Confirmatory,22047800.0,
1048,631930,1,4,,103164944,338,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,22047800.0,
1049,639952,1,4,,103164944,338,Active,,,,,Inhibition of TNF-alpha-induced NF-kappaB activation in human HCT116 cells at 1 mM after 6 hrs by luciferase reporter gene assay,Other,22154834.0,
1050,639955,1,4,,103164944,338,Active,,,,,Inhibition of NF-kappaB-mediated iNOS protein expression in LPS-stimulated mouse RAW264.7 cells at 5 mM by Western blot analysis,Other,22154834.0,
1051,639957,1,4,,103164944,338,Active,,,,,Inhibition of NF-kappaB-mediated iNOS protein expression in LPS-stimulated mouse RAW264.7 cells at 2 to 4 mM by Western blot analysis,Other,22154834.0,
1052,651550,1,1,,8139912,338,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1053,651560,1,1,,8139912,338,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1054,651572,1,2,,8139912,338,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1055,651582,1,1,,8139912,338,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1056,651602,1,1,,8139912,338,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1057,651602,1,1,,8139912,338,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1058,651602,1,1,,8139912,338,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1059,651610,2,1,,8139912,338,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1060,651616,1,1,,8139912,338,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical high throughput confirmation assay for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1061,651631,4,1,,144207002,338,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1062,651631,4,1,,144208669,338,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1063,651631,4,1,,144213426,338,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1064,651632,4,1,,144207002,338,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1065,651632,4,1,,144208669,338,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1066,651632,4,1,,144213426,338,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1067,651633,4,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1068,651633,4,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1069,651633,4,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1070,651634,4,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1071,651634,4,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1072,651634,4,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1073,651635,1,3,,8139912,338,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1074,651636,1,1,,8139912,338,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1075,651640,1,1,,8139912,338,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1076,651644,1,1,,8139912,338,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1077,651647,1,1,,8139912,338,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1078,651654,1,1,,8139912,338,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1079,651658,1,1,,8139912,338,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1080,651660,1,1,,8139912,338,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors             Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1081,651661,2,1,,8139912,338,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1082,651687,1,1,,8139912,338,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1083,651699,1,1,,8139912,338,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1084,651699,1,1,,8139912,338,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1085,651702,1,2,,8139912,338,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1086,651704,2,1,,8139912,338,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1087,651710,1,1,,8139912,338,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1088,651711,2,1,,8139912,338,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1089,651718,1,2,,8139912,338,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1090,651719,1,2,,8139912,338,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
1091,651723,1,1,,8139912,338,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1092,651724,1,1,,8139912,338,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1093,651725,1,1,,8139912,338,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1094,651800,1,1,,8139912,338,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1095,651819,1,1,,8139912,338,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1096,651820,1,1,,8139912,338,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1097,651821,2,4,,8139912,338,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1098,651957,1,1,,8139912,338,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1099,651958,1,1,,8139912,338,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1100,651965,1,1,,8139912,338,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1101,651999,1,1,,8139912,338,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1102,652010,1,1,,8139912,338,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1103,652017,1,1,,8139912,338,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1104,652025,1,1,,8139912,338,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1105,652039,1,1,,8139912,338,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1106,652048,1,2,,8139912,338,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1107,652048,1,2,,144207002,338,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1108,652051,1,1,,8139912,338,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1109,652051,1,1,,144207002,338,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1110,652054,1,1,,8139912,338,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1111,652067,1,4,,8139912,338,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1112,652104,1,1,,8139912,338,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1113,652105,1,1,,8139912,338,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1114,652106,1,1,,8139912,338,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1115,652115,1,1,,8139912,338,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1116,652126,1,3,,8139912,338,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1117,652141,1,1,,8139912,338,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Fluroescence-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) assay to identify assay artifacts,Screening,,
1118,652154,1,1,,8139912,338,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1119,652162,2,1,,8139912,338,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1120,652163,1,1,,8139912,338,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1121,652197,1,1,,8139912,338,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1122,652257,1,1,,8139912,338,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1123,653541,6,1,,103164944,338,Unspecified,,,19400.0,Ki,Inhibition of PTP1B expressed in Escherichia coli BL21 (DE3) cells using p-nitrophenyl phosphate as substrate after 2 to 3 mins by spectrophotometric analysis,Confirmatory,22133902.0,
1124,653544,5,5,,103164944,338,Unspecified,55977766.0,,,IC50,Inhibition of Yersinia pseudotuberculosis YopH,Confirmatory,22133902.0,
1125,666145,2,7,,103164944,338,Unspecified,158931133.0,,250.0,EC50,Plaque growth inhibition,Confirmatory,22211528.0,
1126,678787,3,6,,103164944,338,Unspecified,81886651.0,29509.0,,IC50,TP_TRANSPORTER: inhibition of MTX uptake in Xenopus laevis oocytes,Confirmatory,11099697.0,
1127,678818,2,7,,103164944,338,Unspecified,81871841.0,89776.0,81.2,Km,TP_TRANSPORTER: uptake in Oat2-expressing LLC PK1 cells,Confirmatory,,
1128,678845,1,7,,103164944,338,Unspecified,81891297.0,,,,TP_TRANSPORTER: inhibition of (Ochratoxin A: 0.5uM) of Salicylate at a concentration of 100uM in Oat5-expressing oocytes,Other,15068970.0,
1129,679453,1,8,,103164944,338,Unspecified,124015184.0,19879.0,,,TP_TRANSPORTER: inhibition of benzylpenicillin uptake by Salicylate at a concentration of 1000uM in Oat3-expressing oocyte cells,Other,14762099.0,
1130,679487,1,7,,103164944,338,Unspecified,81886651.0,29509.0,,,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Other,10220563.0,
1131,679522,1,8,,103164944,338,Unspecified,74762955.0,9356.0,,,"TP_TRANSPORTER: inhibition of PAH uptake (PAH: 1 uM, Salicylate: 100 uM) in Xenopus laevis oocytes",Other,10049739.0,
1132,679539,1,8,,103164944,338,Unspecified,74762955.0,9356.0,,,"TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, Salicylate: 1000 uM) in OAT1-expressing S2 cells",Other,12130730.0,
1133,679947,1,7,,103164944,338,Unspecified,1709076.0,25027.0,,,TP_TRANSPORTER: uptake of Salicylic acid at a concentration of 9uM in MCT1-expressing MDA-MB231 cells,Other,10579682.0,
1134,680161,1,8,,103164944,338,Unspecified,313104012.0,11309.0,,,TP_TRANSPORTER: uptake of Salicylic acid at a concentration of 1.43uM in OATP2B1-expressing HEK293 cells,Other,15640378.0,
1135,680187,1,7,,103164944,338,Unspecified,74734337.0,55867.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Salicylate: 500 uM) in Xenopus laevis oocytes",Other,10660625.0,
1136,681046,1,7,,103164944,338,Unspecified,74730587.0,9376.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Salicylate: 5 uM) in Xenopus laevis oocytes",Other,11306713.0,
1137,681118,1,8,,103164944,338,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport in Caco-2 cells,Other,12954186.0,
1138,681141,2,7,,103164944,338,Unspecified,74730587.0,9376.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,11306713.0,
1139,681168,2,7,,103164944,338,Unspecified,124015184.0,19879.0,,Km,TP_TRANSPORTER: uptake in Oat3-expressing oocyte cells,Confirmatory,14762099.0,
1140,681331,3,6,,103164944,338,Unspecified,74762955.0,9356.0,280.0,IC50,TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells,Confirmatory,10929807.0,
1141,681340,3,6,,103164944,338,Unspecified,81886651.0,29509.0,341.0,Ki,TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes,Confirmatory,10220563.0,
1142,681371,2,7,,103164944,338,Unspecified,81879627.0,108114.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,12065749.0,
1143,681372,3,6,,103164944,338,Unspecified,74730587.0,9376.0,1020.0,Ki,TP_TRANSPORTER: inhibition of MTX uptake in OAT3-expressing S2 cells,Confirmatory,12130730.0,
1144,681575,2,7,,103164944,338,Unspecified,81871841.0,89776.0,88.8,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,9650585.0,
1145,686940,1,1,,8139912,338,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1146,686964,1,1,,8139912,338,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1147,686970,1,2,,8139912,338,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1148,686971,1,2,,8139912,338,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1149,686978,1,1,,8139912,338,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1150,686978,1,1,,144207002,338,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1151,686979,1,1,,8139912,338,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1152,686979,1,1,,144207002,338,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1153,686992,2,1,,8139912,338,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
1154,687014,1,1,,8139912,338,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1155,687016,1,1,,8139912,338,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1156,720504,1,1,,8139912,338,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1157,720508,1,1,,8139912,338,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1158,720509,1,1,,8139912,338,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1159,720511,1,1,,8139912,338,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1160,720516,2,1,,144207002,338,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1161,720516,2,1,,144208669,338,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1162,720516,2,1,,144213426,338,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1163,720532,1,1,,29215390,338,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1164,720532,1,1,,144207002,338,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1165,720533,1,1,,29215390,338,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1166,720533,1,1,,144207002,338,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1167,720542,1,2,,8139912,338,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1168,720543,1,1,,8139912,338,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1169,720551,1,2,,8139912,338,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1170,720552,2,1,,144207002,338,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1171,720552,2,1,,144208669,338,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1172,720552,2,1,,144213426,338,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1173,720553,1,2,,8139912,338,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1174,720579,2,1,,8139912,338,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1175,720580,1,1,,8139912,338,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1176,720582,1,1,,8139912,338,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1177,720596,1,1,,8139912,338,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1178,720634,2,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1179,720634,2,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1180,720634,2,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1181,720635,2,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1182,720635,2,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1183,720635,2,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1184,720637,2,1,,144207002,338,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1185,720637,2,1,,144208669,338,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1186,720637,2,1,,144213426,338,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1187,720647,1,2,,8139912,338,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
1188,720648,1,1,,8139912,338,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1189,720674,2,2,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1190,720674,2,2,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1191,720674,2,2,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1192,720675,2,2,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1193,720675,2,2,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1194,720675,2,2,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1195,720678,2,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1196,720678,2,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1197,720678,2,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1198,720679,2,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1199,720679,2,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1200,720679,2,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1201,720680,2,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1202,720680,2,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1203,720680,2,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1204,720681,2,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1205,720681,2,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1206,720681,2,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1207,720682,2,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1208,720682,2,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1209,720682,2,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1210,720683,2,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1211,720683,2,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1212,720683,2,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1213,720684,2,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1214,720684,2,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1215,720684,2,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1216,720685,2,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1217,720685,2,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1218,720685,2,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1219,720686,2,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1220,720686,2,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1221,720686,2,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1222,720687,2,2,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1223,720687,2,2,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1224,720687,2,2,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1225,720691,4,1,,144207002,338,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1226,720691,4,1,,144208669,338,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1227,720691,4,1,,144213426,338,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1228,720692,3,1,,144207002,338,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1229,720692,3,1,,144208669,338,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1230,720692,3,1,,144213426,338,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1231,720693,3,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1232,720693,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1233,720693,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1234,720700,1,4,,8139912,338,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1235,720702,1,1,,8139912,338,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1236,720704,1,4,,8139912,338,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1237,720707,1,2,,8139912,338,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1238,720708,1,2,,8139912,338,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1239,720709,1,2,,8139912,338,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1240,720711,1,2,,8139912,338,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1241,720719,2,1,,144207002,338,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1242,720719,2,1,,144208669,338,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1243,720719,2,1,,144213426,338,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1244,720725,2,1,,144207002,338,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1245,720725,2,1,,144208669,338,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1246,720725,2,1,,144213426,338,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1247,732288,1,2,,103164944,338,Active,,,,,Antiinflammatory activity in human macrophages assessed as inhibition of LPS-induced IL-8 release at 10 uM preincubated for 30 mins before LPS-challenge measured after 24 hrs post challenge by ELISA,Other,23416190.0,
1248,732289,1,2,,103164944,338,Active,,,,,Antiinflammatory activity in human macrophages assessed as inhibition of LPS-induced IL-1beta release at 10 uM preincubated for 30 mins before LPS-challenge measured after 24 hrs post challenge by ELISA,Other,23416190.0,
1249,732290,1,2,,103164944,338,Active,,,,,Antiinflammatory activity in human macrophages assessed as inhibition of LPS-induced TNFalpha release at 10 uM preincubated for 30 mins before LPS-challenge measured after 24 hrs post challenge by ELISA,Other,23416190.0,
1250,743012,3,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1251,743012,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1252,743012,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1253,743014,3,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1254,743014,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1255,743014,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1256,743015,3,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1257,743015,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1258,743015,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1259,743033,3,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1260,743033,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1261,743033,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1262,743035,2,1,,144207002,338,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1263,743035,2,1,,144208669,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1264,743035,2,1,,144213426,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1265,743036,2,1,,144207002,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1266,743036,2,1,,144208669,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1267,743036,2,1,,144213426,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1268,743040,3,1,,144207002,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1269,743040,3,1,,144208669,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1270,743040,3,1,,144213426,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1271,743041,3,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1272,743041,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1273,743041,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1274,743042,3,1,,144207002,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1275,743042,3,1,,144208669,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1276,743042,3,1,,144213426,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1277,743053,2,1,,144207002,338,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1278,743053,2,1,,144208669,338,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1279,743053,2,1,,144213426,338,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1280,743054,2,1,,144207002,338,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1281,743054,2,1,,144208669,338,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1282,743054,2,1,,144213426,338,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1283,743063,2,1,,144207002,338,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1284,743063,2,1,,144208669,338,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1285,743063,2,1,,144213426,338,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1286,743064,3,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1287,743064,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1288,743064,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1289,743065,3,1,,144207002,338,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1290,743065,3,1,,144208669,338,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1291,743065,3,1,,144213426,338,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1292,743066,3,1,,144207002,338,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1293,743066,3,1,,144208669,338,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1294,743066,3,1,,144213426,338,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1295,743067,2,1,,144207002,338,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1296,743067,2,1,,144208669,338,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1297,743067,2,1,,144213426,338,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1298,743069,2,1,,144207002,338,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1299,743069,2,1,,144208669,338,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1300,743069,2,1,,144213426,338,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1301,743074,2,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1302,743074,2,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1303,743074,2,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1304,743075,2,1,,144207002,338,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1305,743075,2,1,,144208669,338,Inactive,348019627.0,2099.0,2.5004,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1306,743075,2,1,,144213426,338,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1307,743077,2,1,,144207002,338,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1308,743077,2,1,,144208669,338,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1309,743077,2,1,,144213426,338,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1310,743078,2,1,,144207002,338,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1311,743078,2,1,,144208669,338,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1312,743078,2,1,,144213426,338,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1313,743079,3,1,,144207002,338,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1314,743079,3,1,,144208669,338,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1315,743079,3,1,,144213426,338,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1316,743080,3,1,,144207002,338,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1317,743080,3,1,,144208669,338,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1318,743080,3,1,,144213426,338,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1319,743081,3,1,,144207002,338,Inconclusive,,,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1320,743081,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1321,743081,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1322,743083,3,1,,144207002,338,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1323,743083,3,1,,144208669,338,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1324,743083,3,1,,144213426,338,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1325,743084,3,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1326,743084,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1327,743084,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1328,743085,3,1,,144207002,338,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1329,743085,3,1,,144208669,338,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1330,743085,3,1,,144213426,338,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1331,743086,3,1,,144207002,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1332,743086,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1333,743086,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1334,743091,2,1,,144207002,338,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1335,743091,2,1,,144208669,338,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1336,743091,2,1,,144213426,338,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1337,743094,3,1,,144207002,338,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1338,743094,3,1,,144208669,338,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1339,743094,3,1,,144213426,338,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1340,743122,2,1,,144207002,338,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1341,743122,2,1,,144208669,338,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1342,743122,2,1,,144213426,338,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1343,743126,1,1,,8139912,338,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1344,743139,2,1,,144207002,338,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1345,743139,2,1,,144208669,338,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1346,743139,2,1,,144213426,338,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1347,743140,2,1,,144207002,338,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1348,743140,2,1,,144208669,338,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1349,743140,2,1,,144213426,338,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1350,743191,3,1,,144208669,338,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1351,743191,3,1,,144213426,338,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1352,743194,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1353,743194,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1354,743199,2,1,,144208669,338,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1355,743199,2,1,,144213426,338,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1356,743202,4,1,,144208669,338,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1357,743202,4,1,,144213426,338,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1358,743203,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1359,743203,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1360,743209,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1361,743209,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1362,743210,4,1,,144208669,338,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1363,743210,4,1,,144213426,338,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1364,743211,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1365,743211,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1366,743212,3,1,,144208669,338,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1367,743212,3,1,,144213426,338,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1368,743213,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1369,743213,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1370,743215,3,1,,144208669,338,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1371,743215,3,1,,144213426,338,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1372,743217,3,1,,144208669,338,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1373,743217,3,1,,144213426,338,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1374,743218,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1375,743218,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1376,743219,3,1,,144208669,338,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1377,743219,3,1,,144213426,338,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1378,743220,3,1,,144208669,338,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1379,743220,3,1,,144213426,338,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1380,743221,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1381,743221,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1382,743222,3,1,,144208669,338,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1383,743222,3,1,,144213426,338,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1384,743223,3,1,,144208669,338,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1385,743223,3,1,,144213426,338,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1386,743224,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1387,743224,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1388,743225,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1389,743225,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1390,743226,2,1,,144208669,338,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1391,743226,2,1,,144213426,338,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1392,743227,2,1,,144208669,338,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1393,743227,2,1,,144213426,338,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1394,743228,3,1,,144208669,338,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1395,743228,3,1,,144213426,338,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1396,743238,1,1,,8139912,338,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
1397,743239,2,1,,144208669,338,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1398,743239,2,1,,144213426,338,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1399,743240,2,1,,144208669,338,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1400,743240,2,1,,144213426,338,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1401,743241,2,1,,144208669,338,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1402,743241,2,1,,144213426,338,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1403,743242,2,1,,144208669,338,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1404,743242,2,1,,144213426,338,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1405,743244,1,1,,144207002,338,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1406,743247,1,2,,8139912,338,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1407,743255,1,1,,8139912,338,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
1408,743266,1,2,,8139912,338,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
1409,743269,1,1,,8139912,338,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1410,743269,1,1,,8139912,338,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1411,743279,1,2,,8139912,338,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
1412,743397,1,1,,8139912,338,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1413,743398,1,1,,8139912,338,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1414,743966,1,1,,103164944,338,Unspecified,,,,,Inhibition of quorum sensing system in Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of biofilm formation at 4 mM after 24 hrs by crystal violet staining method relative to control,Other,23489623.0,
1415,743972,1,1,,103164944,338,Unspecified,,,,,Inhibition of quorum sensing system in Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of twitching motility at 0.1 to 0.5 mM after 24 hrs relative to control,Other,23489623.0,
1416,743973,1,1,,103164944,338,Unspecified,,,,,Inhibition of quorum sensing system in Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of swimming motility at 0.1 to 0.5 mM after 24 hrs relative to control,Other,23489623.0,
1417,743974,1,1,,103164944,338,Unspecified,,,,,Inhibition of quorum sensing system in Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of swarming motility at 0.1 to 0.5 mM after 24 hrs relative to control,Other,23489623.0,
1418,766251,1,1,,103164944,338,Unspecified,,,,,Inhibition of recombinant SPM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using FC4 as substrate assessed as residual activity at 1 mM preincubated for 10 mins prior to substrate addition by fluorescence-based assay relative to control,Other,23898798.0,
1419,781325,1,2,,103164944,338,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 2009,Other,24249037.0,
1420,781326,1,2,,103164944,338,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
1421,925570,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020610,Other,,
1422,925571,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020610,Other,,
1423,925572,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020610,Other,,
1424,925573,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020610,Other,,
1425,925574,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020610,Other,,
1426,925575,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020610,Other,,
1427,926203,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020610",Other,,
1428,926204,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020610,Other,,
1429,928218,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020610,Other,,
1430,928219,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020610,Other,,
1431,928220,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020610,Other,,
1432,928221,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020610,Other,,
1433,928222,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020610,Other,,
1434,928223,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020610,Other,,
1435,928224,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020610,Other,,
1436,928225,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020610,Other,,
1437,928226,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020610,Other,,
1438,928227,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020610,Other,,
1439,928228,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020610,Other,,
1440,938212,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020610,Other,,
1441,938213,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020610,Other,,
1442,938214,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020610",Other,,
1443,938215,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020610,Other,,
1444,938216,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020610,Other,,
1445,938217,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020610,Other,,
1446,938848,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020610,Other,,
1447,938849,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020610,Other,,
1448,938850,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020610,Other,,
1449,938851,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020610,Other,,
1450,938852,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020610,Other,,
1451,938853,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020610,Other,,
1452,938854,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020610,Other,,
1453,938855,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020610,Other,,
1454,940874,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020610,Other,,
1455,940875,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020610,Other,,
1456,940876,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020610,Other,,
1457,940877,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020610,Other,,
1458,940878,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020610,Other,,
1459,949779,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020610,Other,,
1460,949780,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020610,Other,,
1461,949781,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020610,Other,,
1462,949782,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020610,Other,,
1463,951804,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020610,Other,,
1464,951805,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020610,Other,,
1465,951806,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020610,Other,,
1466,951807,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020610,Other,,
1467,951808,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020610,Other,,
1468,951809,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020610,Other,,
1469,951810,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020610,Other,,
1470,951811,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020610,Other,,
1471,951812,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020610,Other,,
1472,951813,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020610,Other,,
1473,951814,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020610,Other,,
1474,951815,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020610,Other,,
1475,951816,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020610,Other,,
1476,951817,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020610,Other,,
1477,951818,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020610,Other,,
1478,969262,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020610,Other,,
1479,969263,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020610,Other,,
1480,969264,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020610,Other,,
1481,969265,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020610,Other,,
1482,969266,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020610,Other,,
1483,969267,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020610,Other,,
1484,969268,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020610,Other,,
1485,969269,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020610,Other,,
1486,969270,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020610,Other,,
1487,969271,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020610,Other,,
1488,969272,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020610,Other,,
1489,969273,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020610,Other,,
1490,969274,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020610,Other,,
1491,969275,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020610,Other,,
1492,969276,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020610,Other,,
1493,969277,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020610,Other,,
1494,969278,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020610,Other,,
1495,969279,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020610,Other,,
1496,969912,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020610,Other,,
1497,1005545,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020610",Other,,
1498,1005546,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020610",Other,,
1499,1005547,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020610",Other,,
1500,1005548,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020610",Other,,
1501,1005549,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020610",Other,,
1502,1005550,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020610",Other,,
1503,1005551,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020610,Other,,
1504,1005552,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020610,Other,,
1505,1005553,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020610",Other,,
1506,1005554,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020610",Other,,
1507,1005555,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020610",Other,,
1508,1005556,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020610",Other,,
1509,1005557,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020610,Other,,
1510,1005558,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020610",Other,,
1511,1005559,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020610",Other,,
1512,1005560,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020610",Other,,
1513,1005561,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020610",Other,,
1514,1005562,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020610,Other,,
1515,1005563,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020610",Other,,
1516,1007427,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020610",Other,,
1517,1007428,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020610",Other,,
1518,1007429,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020610",Other,,
1519,1007430,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020610",Other,,
1520,1007431,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020610",Other,,
1521,1007432,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020610",Other,,
1522,1007433,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020610,Other,,
1523,1007434,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020610",Other,,
1524,1007435,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020610",Other,,
1525,1007436,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020610",Other,,
1526,1007437,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020610,Other,,
1527,1007438,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020610",Other,,
1528,1007439,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020610",Other,,
1529,1007440,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020610",Other,,
1530,1007441,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020610",Other,,
1531,1008021,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020610",Other,,
1532,1008022,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020610",Other,,
1533,1012963,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020610",Other,,
1534,1012964,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020610",Other,,
1535,1012965,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020610",Other,,
1536,1014831,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020610",Other,,
1537,1014832,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020610",Other,,
1538,1014833,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020610",Other,,
1539,1014834,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020610,Other,,
1540,1014835,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020610",Other,,
1541,1014836,1,3,,103164944,338,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020610,Other,,
1542,1014837,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020610",Other,,
1543,1014838,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020610",Other,,
1544,1014839,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020610",Other,,
1545,1014840,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020610",Other,,
1546,1014841,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020610",Other,,
1547,1014842,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020610",Other,,
1548,1014843,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020610",Other,,
1549,1014844,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020610",Other,,
1550,1014845,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020610",Other,,
1551,1014846,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020610",Other,,
1552,1014847,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020610",Other,,
1553,1014848,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020610",Other,,
1554,1014849,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020610",Other,,
1555,1014850,1,3,,103164944,338,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: subcutaneous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020610",Other,,
1556,1053175,2,1,,178127199,338,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
1557,1053188,2,1,,8139912,338,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1558,1053197,1,1,,8139912,338,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
1559,1059430,1,4,,103164944,338,Unspecified,123948.0,3620.0,,,Inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 using L-tryptophan as substrate at 1 mM after 1 hr relative to control,Other,24262887.0,
1560,1075889,1,4,,103164944,338,Unspecified,109940048.0,280960.0,100000.0,Ki,Reversible inhibition of bovine xanthine oxidase,Confirmatory,24508129.0,
1561,1083148,1,1,,103164944,338,Active,,,,,Nematotoxic activity against freshly hatched Meloidogyne incognita J2 (root-knot nematode) isolated from tomato roots assessed as induction of nematode paralysis at 1000 ug/mL measured 24 hr after immersion in compound test solutions,Other,23136941.0,
1562,1083149,1,1,,103164944,338,Unspecified,,,,,Nematotoxic activity against freshly hatched Meloidogyne incognita J2 (root-knot nematode) isolated from tomato roots assessed as induction of nematode paralysis measured 24 hr after immersion in compound test solutions,Other,23136941.0,
1563,1083150,1,1,,103164944,338,Unspecified,,,,,Nematotoxic activity against Meloidogyne incognita (root-knot nematode),Other,23136941.0,
1564,1085477,1,4,,103164944,338,Unspecified,146345377.0,2990.0,,,Inhibition of beta-glucuronidase (unknown origin) using p-nitrophenyl-beta-D-glucopyranosiduronic acid as substrate at 1 mM after 30 min,Other,,
1565,1085478,1,3,,103164944,338,Unspecified,136408.0,5644.0,,,Inhibition of trypsin (unknown origin) assessed as hydrolysis of bovine serum albumin at 1 mM after 20 min,Other,,
1566,1085478,1,3,,103164944,338,Unspecified,136413.0,5645.0,,,Inhibition of trypsin (unknown origin) assessed as hydrolysis of bovine serum albumin at 1 mM after 20 min,Other,,
1567,1085478,1,3,,103164944,338,Unspecified,209572698.0,5646.0,,,Inhibition of trypsin (unknown origin) assessed as hydrolysis of bovine serum albumin at 1 mM after 20 min,Other,,
1568,1086159,1,4,,103164944,338,Unspecified,146345377.0,2990.0,,,Inhibition of beta-glucuronidase (unknown origin) using p-nitrophenyl-beta-D-glucopyranosiduronic acid as substrate at 1 uM after 30 min by spectrophotometric analysis,Other,,
1569,1086160,1,3,,103164944,338,Unspecified,136408.0,5644.0,,,Inhibition of trypsin (unknown origin) using bovine serum albumin as substrate at 1 uM incubated for 20 min prior to substrate addition measured after 25 min by Lowry method,Other,,
1570,1086160,1,3,,103164944,338,Unspecified,136413.0,5645.0,,,Inhibition of trypsin (unknown origin) using bovine serum albumin as substrate at 1 uM incubated for 20 min prior to substrate addition measured after 25 min by Lowry method,Other,,
1571,1086160,1,3,,103164944,338,Unspecified,209572698.0,5646.0,,,Inhibition of trypsin (unknown origin) using bovine serum albumin as substrate at 1 uM incubated for 20 min prior to substrate addition measured after 25 min by Lowry method,Other,,
1572,1088396,1,1,,103164944,338,Unspecified,,,,,Induction of systemic acquired resistance against Blumeria graminis f. sp. tritici in Triticum aestivum (wheat) plants on Kanzler cultivar assessed as decrease in disease severity of powdery mildew in leaves infected with Triticum aestivum (wheat) exposed to 1 mM compound for 3 years by small-plot experiment relative to control,Other,23731643.0,
1573,1088599,1,1,,103164944,338,Unspecified,,,,,Induction of systemic acquired resistance against Pythium debaryanum AUSB 26351 in Gossypium barbadense seeds assessed as increase of fresh weight of seedling under greenhouse condition at 5 mM after 7 days,Other,23731643.0,
1574,1088601,1,1,,103164944,338,Unspecified,,,,,Induction of systemic acquired resistance against Pythium debaryanum AUSB 26351 in Gossypium barbadense seeds assessed as increase of dry weight of seedling under greenhouse condition at 5 mM after 7 days,Other,23731643.0,
1575,1088602,1,1,,103164944,338,Unspecified,,,,,Induction of systemic acquired resistance against Pythium debaryanum AUSB 26351 in Gossypium barbadense seeds assessed as reduction of disease index for germination under greenhouse condition at 5 mM after 7 days relative to infected control,Other,23731643.0,
1576,1088604,1,1,,103164944,338,Unspecified,,,,,Induction of systemic acquired resistance against Pythium debaryanum AUSB 26351 in Gossypium barbadense seeds assessed as increase of germination under greenhouse condition at 5 mM after 7 days relative to control,Other,23731643.0,
1577,1088606,1,1,,103164944,338,Unspecified,,,,,Induction of systemic acquired resistance against Fusarium oxysporum AUSB 26325 in Gossypium barbadense seeds assessed as increase of dry weight of seedling under greenhouse condition at 5 mM after 7 days,Other,23731643.0,
1578,1088608,1,1,,103164944,338,Unspecified,,,,,Induction of systemic acquired resistance against Fusarium oxysporum AUSB 26325 in Gossypium barbadense seeds assessed as increase of fresh weight of seedling under greenhouse condition at 5 mM after 7 days,Other,23731643.0,
1579,1088610,1,1,,103164944,338,Unspecified,,,,,Induction of systemic acquired resistance against Fusarium oxysporum AUSB 26325 in Gossypium barbadense seeds assessed as reduction of disease index for germination under greenhouse condition at 5 mM after 7 days relative to infected control,Other,23731643.0,
1580,1088612,1,1,,103164944,338,Unspecified,,,,,Induction of systemic acquired resistance against Fusarium oxysporum AUSB 26325 in Gossypium barbadense seeds assessed as increase of germination under greenhouse condition at 5 mM after 7 days relative to control,Other,23731643.0,
1581,1088664,1,1,,103164944,338,Unspecified,,,,,Toxicity in Cucurbita pepo (pumpkin) assessed as effect on host weight and height under greenhouse condition at 25 to 50 ug/ml,Other,23731643.0,
1582,1088665,1,1,,103164944,338,Active,,,,,Insecticidal activity against Phytophthora capsici in Cucurbita pepo assessed as effect on host weight and height under greenhouse condition at 25 to 50 ug/ml,Other,23731643.0,
1583,1088668,1,1,,103164944,338,Active,,,,,Insecticidal activity against Phytophthora capsici in Cucurbita pepo assessed as reduction of disease severity under greenhouse condition at 25 ug/ml after 1 week,Other,23731643.0,
1584,1088671,1,1,,103164944,338,Active,,,,,Insecticidal activity against Phytophthora capsici assessed as inhibition of sporangium production at =>100 ug/ml after 4 days,Other,23731643.0,
1585,1088674,1,1,,103164944,338,Active,,,,,Insecticidal activity against Phytophthora capsici assessed as inhibition of zoospore germination at 500 to 1000 ug/ml after 4 days with 16 hr photoperiod,Other,23731643.0,
1586,1088677,1,1,,103164944,338,Active,,,,,Insecticidal activity against Phytophthora capsici assessed as inhibition of mycelial growth by measuring perpendicular colony diameter at => 100 ug/ml after 8 days,Other,23731643.0,
1587,1090826,1,1,,103164944,338,Unspecified,,,,,Antifeedant activity against Hylobius abietis (pine weevil ) in compound pre-treated Scots pine twig at 50 mM measured after 24 hr by two-choice laboratory bioassay,Other,17927202.0,
1588,1091955,1,2,,103164944,338,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.3",Other,20879794.0,
1589,1091956,1,1,,103164944,338,Unspecified,,,,,"Apparent hydrophobicity, log D of the compound in Octanol-buffer",Other,20879794.0,
1590,1091957,1,1,,103164944,338,Unspecified,,,,,Apparent permeability of the compound by PAMPA,Other,20879794.0,
1591,1091958,2,1,,103164944,338,Unspecified,,,,,"Hydrophobicity, log P of the compound in octanol-water by shaking-flask method",Other,20879794.0,
1592,1092701,1,1,,103164944,338,Inactive,,,,,Antifungal activity against Rhizoctonia solani AG-1 IA assessed as inhibition of mycelial growth at < 10 mg/l relative to control,Other,23731643.0,
1593,1092704,1,1,,103164944,338,Active,,,,,Induction of systemic acquired resistance in Glycine max (soybean) plant infected with Rhizoctonia solani AG-1 IA assessed as reduction in disease severity at 2.5 mM applied as spray on day 20 prior to inoculation measured after 5 to 10 days relative to control,Other,23731643.0,
1594,1092708,1,1,,103164944,338,Unspecified,,,,,Antifungal activity against Rhizoctonia solani AG-1 IA assessed as mycelial growth at 100 mg/l (Rvb = 40 mm),Other,23731643.0,
1595,1092710,1,1,,103164944,338,Unspecified,,,,,Antifungal activity against Rhizoctonia solani AG-1 IA assessed as mycelial growth at 10 mg/l (Rvb = 40 mm),Other,23731643.0,
1596,1092712,1,1,,103164944,338,Unspecified,,,,,Antifungal activity against Rhizoctonia solani AG-1 IA assessed as mycelial growth at 1 mg/l (Rvb = 40 mm),Other,23731643.0,
1597,1092713,1,1,,103164944,338,Unspecified,,,,,Antifungal activity against Rhizoctonia solani AG-1 IA assessed as mycelial growth at 0.1 mg/l (Rvb = 40 mm),Other,23731643.0,
1598,1094682,1,2,,103164944,338,Unspecified,,,,,Toxicity in po dosed Rattus norvegicus (rat),Other,,
1599,1098137,1,1,,103164944,338,Active,,,,,Increase of new ploypeptide content in Curcuma longa (turmeric) plant rhizomes at 0.5 to 1 mM after 1 to 2 hr by SDS-PAGE analysis,Other,23731643.0,
1600,1098138,1,1,,103164944,338,Active,,,,,Antimicrobial activity against Pythium aphanidermatum infected turmeric plant rhizomes assessed as increase of peroxidase activity at 0.5 mM after 2 to 10 days,Other,23731643.0,
1601,1098139,1,1,,103164944,338,Unspecified,,,,,Antimicrobial activity against Pythium aphanidermatum infected turmeric plant rhizomes assessed as increase of trypsin inhibitor activity at 0.5 mM after 2 to 10 days relative to control,Other,23731643.0,
1602,1098140,1,1,,103164944,338,Unspecified,,,,,Antimicrobial activity against Pythium aphanidermatum infected turmeric plant rhizomes assessed as increase of chymotrypsin inhibitor activity at 0.5 mM after 2 to 10 days relative to control,Other,23731643.0,
1603,1098141,1,1,,103164944,338,Active,,,,,Antimicrobial activity against Pythium aphanidermatum infected turmeric plant rhizomes assessed as increase of chymotrypsin inhibitor activity at 0.5 mM after 2 to 6 days,Other,23731643.0,
1604,1098142,1,1,,103164944,338,Unspecified,,,,,Increase of chymotrypsin inhibitor activity in Curcuma longa (turmeric) plant rhizomes at 0.5 to 1 mM after 30 min to 2 hr,Other,23731643.0,
1605,1098143,1,1,,103164944,338,Active,,,,,Increase of trypsin inhibitor activity in Curcuma longa (turmeric) plant rhizomes at 0.5 mM after 30 to 60 min,Other,23731643.0,
1606,1098144,1,1,,103164944,338,Active,,,,,Antimicrobial activity against Pythium aphanidermatum infected in turmeric plant rhizomes assessed as reduction of cell death at 0.5 to 1 mM after 2 to 8 days,Other,23731643.0,
1607,1098145,1,1,,103164944,338,Active,,,,,Increase of soluble peroxidase activity in Curcuma longa (turmeric) plant rhizomes at 0.5 mM after 2 hr,Other,23731643.0,
1608,1098146,1,1,,103164944,338,Inactive,,,,,Increase of ionically bound peroxidase activity in Curcuma longa (turmeric) plant rhizomes at 1 mM after 2 hr,Other,23731643.0,
1609,1098147,1,1,,103164944,338,Unspecified,,,,,Increase of ionically bound peroxidase activity in Curcuma longa (turmeric) plant rhizomes at 0.5 mM after 2 hr relative to control,Other,23731643.0,
1610,1098148,1,1,,103164944,338,Unspecified,,,,,Increase of soluble peroxidase activity in Curcuma longa (turmeric) plant rhizomes at 0.5 mM after 1 hr relative to control,Other,23731643.0,
1611,1098149,1,1,,103164944,338,Active,,,,,Increase of soluble peroxidase activity in Curcuma longa (turmeric) plant rhizomes at 0.5 to 1 mM after 15 min,Other,23731643.0,
1612,1098150,1,1,,103164944,338,Active,,,,,Increase of protein content in Curcuma longa (turmeric) plant rhizomes at 1 mM,Other,23731643.0,
1613,1098151,1,1,,103164944,338,Active,,,,,Increase of protein content in Curcuma longa (turmeric) plant rhizomes at 1 mM up to 1 hr,Other,23731643.0,
1614,1098152,1,1,,103164944,338,Active,,,,,Antimicrobial activity against Pythium aphanidermatum infected turmeric plant rhizomes assessed as increase of trypsin inhibitor activity at 0.5 mM after 2 to 8 days,Other,23731643.0,
1615,1100608,1,1,,103164944,338,Unspecified,,,,,Antibacterial activity against Ralstonia solanacearum grown on potato semi-synthetic agar medium at 5 umol/disk by paper disk method,Other,84.0,
1616,1100609,1,1,,103164944,338,Inactive,,,,,Antibacterial activity against Ralstonia solanacearum grown on potato semi-synthetic agar medium at 0.5 umol/disk by paper disk method,Other,84.0,
1617,1104045,1,1,,103164944,338,Active,,,,,Induction of systemic resistance (ISR) activity in Nicotiana tabacum (tobacco) seedlings against pectobacterium carotovorum subsp. carotovorum SCC1 assessed as decrease in disease symptoms on leaves at 1 mM applied to roots prior to leaf infection with SCC1 measured at 3 days after pathogen challenge,Other,19504536.0,
1618,1107734,1,1,,103164944,338,Inactive,,,,,Decrease in Botryosphaeria dothidea ligninolytic enzyme production assessed as pectinase activity using pectin as substrate at 1 mM measured at 28 degC after 4 days,Other,23731643.0,
1619,1107735,1,1,,103164944,338,Inactive,,,,,Decrease in Neofusicoccum ribis ligninolytic enzyme production assessed as pectinase activity using pectin as substrate measured at 28 degC after 4 days,Other,23731643.0,
1620,1107736,1,1,,103164944,338,Unspecified,,,,,Decrease in Lasiodiplodia theobromae ligninolytic enzyme production assessed as pectinase activity using pectin as substrate at 25 mM measured at 28 degC after 4 days,Other,23731643.0,
1621,1107738,1,1,,103164944,338,Active,,,,,Decrease in Botryosphaeria dothidea ligninolytic enzyme production assessed as laccase activity using ABTS as substrate at 15 mM measured at 28 degC after 4 days,Other,23731643.0,
1622,1107740,1,1,,103164944,338,Active,,,,,Decrease in Botryosphaeria dothidea ligninolytic enzyme production assessed as laccase activity using ABTS as substrate measured at 28 degC after 4 days,Other,23731643.0,
1623,1107741,1,1,,103164944,338,Unspecified,,,,,Decrease in Lasiodiplodia theobromae ligninolytic enzyme production assessed as laccase activity using ABTS as substrate at 1 mM measured at 28 degC after 4 days,Other,23731643.0,
1624,1107745,1,1,,103164944,338,Unspecified,,,,,Decrease in Lasiodiplodia theobromae mycelium biomass production measured at 28 degC after 4 days by gravimetric analysis,Other,23731643.0,
1625,1107746,1,1,,103164944,338,Unspecified,,,,,Decrease in Diplodia seriata (Schwein.) Shoemaker mycelium biomass production measured at 28 degC after 4 days by gravimetric analysis,Other,23731643.0,
1626,1107747,1,1,,103164944,338,Unspecified,,,,,Decrease in Neofusicoccum ribis mycelium biomass production at 25 mM measured at 28 degC after 4 days by gravimetric analysis,Other,23731643.0,
1627,1107751,1,1,,103164944,338,Active,,,,,Inhibition of Diplodia seriata (Schwein.) Shoemaker mycelium growth at 15 mM measured at 28 degC after 4 days,Other,23731643.0,
1628,1107755,1,1,,103164944,338,Active,,,,,Inhibition of Neofusicoccum ribis mycelium growth at 20 mM measured at 28 degC after 4 days,Other,23731643.0,
1629,1107757,1,1,,103164944,338,Unspecified,,,,,Inhibition of Lasiodiplodia theobromae mycelium growth at 25 mM measured at 28 degC after 4 days,Other,23731643.0,
1630,1107760,1,1,,103164944,338,Unspecified,,,,,Inhibition of Lasiodiplodia theobromae mycelium growth measured at 28 degC after 4 days,Other,23731643.0,
1631,1107761,1,1,,103164944,338,Unspecified,,,,,Inhibition of Neofusicoccum ribis mycelium growth measured at 28 degC after 4 days,Other,23731643.0,
1632,1107762,1,1,,103164944,338,Unspecified,,,,,Inhibition of Diplodia seriata (Schwein.) Shoemaker mycelium growth measured at 28 degC after 4 days,Other,23731643.0,
1633,1107763,1,1,,103164944,338,Unspecified,,,,,Inhibition of Botryosphaeria dothidea mycelium growth measured at 28 degC after 4 days,Other,23731643.0,
1634,1117319,1,2,,8139912,338,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
1635,1117319,1,2,,8139912,338,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
1636,1136196,1,1,,103164944,338,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced foot edema in rat administered via gastric gavage,Other,309947.0,
1637,1136212,1,1,,103164944,338,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema,Other,309948.0,
1638,1136213,1,1,,103164944,338,Unspecified,,,,,Analgesic activity in po dosed rat by hyperesthesia test,Other,309948.0,
1639,1145605,2,1,,103164944,338,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,13215.0,
1640,1145606,2,1,,103164944,338,Unspecified,,,,,"Octanol-aqueous phase partition coefficient, log P of the compound",Other,13215.0,
1641,1145607,1,1,,103164944,338,Unspecified,,,,,"Octanol-aqueous phase distribution coefficient, log D of the compound",Other,13215.0,
1642,1145608,1,1,,103164944,338,Unspecified,,,,,Drug absorption in anesthetized rat colon at pH 6.8,Other,13215.0,
1643,1145610,1,1,,103164944,338,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 6.8",Other,13215.0,
1644,1145614,1,1,,103164944,338,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,13215.0,
1645,1145615,1,1,,103164944,338,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.8",Other,13215.0,
1646,1159387,1,2,,103164944,338,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
1647,1159509,1,1,,144208669,338,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1648,1159509,1,1,,144213426,338,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1649,1159515,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1650,1159515,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1651,1159516,1,1,,144208669,338,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1652,1159516,1,1,,144213426,338,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1653,1159517,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1654,1159517,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1655,1159518,1,1,,144208669,338,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1656,1159518,1,1,,144213426,338,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1657,1159519,1,1,,144208669,338,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1658,1159519,1,1,,144213426,338,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1659,1159520,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1660,1159520,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1661,1159521,1,1,,144208669,338,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1662,1159521,1,1,,144213426,338,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1663,1159523,1,1,,144208669,338,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1664,1159523,1,1,,144213426,338,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1665,1159524,1,1,,8139912,338,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1666,1159525,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1667,1159525,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1668,1159526,1,1,,144208669,338,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1669,1159526,1,1,,144213426,338,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1670,1159527,1,1,,144208669,338,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1671,1159527,1,1,,144213426,338,Inconclusive,325495497.0,6256.0,43.6465,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1672,1159528,1,1,,144208669,338,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1673,1159528,1,1,,144213426,338,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1674,1159529,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1675,1159529,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1676,1159531,1,1,,144208669,338,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1677,1159531,1,1,,144213426,338,Inconclusive,325495497.0,6256.0,38.9,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1678,1159551,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1679,1159551,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1680,1159552,1,1,,144208669,338,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1681,1159552,1,1,,144213426,338,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1682,1159553,2,1,,144208669,338,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1683,1159553,2,1,,144213426,338,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1684,1159555,1,1,,144208669,338,Inconclusive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1685,1159555,1,1,,144213426,338,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1686,1159583,2,1,,178127199,338,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
1687,1159606,1,1,,8139912,338,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
1688,1159607,2,1,,312995495,338,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1689,1159620,1,1,,103164944,338,Active,,,,,Summary of drug indications.,Other,,
1690,1163259,1,1,,103164944,338,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as survival rate at 10 uM after 24 hrs by MTT assay,Other,25200306.0,
1691,1163260,1,1,,103164944,338,Unspecified,,,40.0,CC50,Cytotoxicity against mouse RAW264.7 cells assessed as reduction in survival rate after 24 hrs by MTT assay,Confirmatory,25200306.0,
1692,1163261,1,1,,103164944,338,Unspecified,,,,,Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as TRAP+ multinucleated cells level at 10 uM incubated for 4 days by TRAP staining assay,Other,25200306.0,
1693,1167300,1,2,,103164944,338,Unspecified,,,278303.0,IC50,Antioxidant activity assessed as DPPH radical scavenging activity incubated at room temperature for 20 mins by UV-visible spectrophotometry,Confirmatory,25278230.0,
1694,1189226,1,2,,103164944,338,Unspecified,1703037.0,5571.0,,,Activation of AMPK in HEK293 cells relative to control,Other,25122135.0,
1695,1189226,1,2,,103164944,338,Unspecified,3912957.0,5565.0,,,Activation of AMPK in HEK293 cells relative to control,Other,25122135.0,
1696,1189226,1,2,,103164944,338,Unspecified,14194425.0,5564.0,,,Activation of AMPK in HEK293 cells relative to control,Other,25122135.0,
1697,1189226,1,2,,103164944,338,Unspecified,14285344.0,51422.0,,,Activation of AMPK in HEK293 cells relative to control,Other,25122135.0,
1698,1189226,1,2,,103164944,338,Unspecified,20178276.0,5563.0,,,Activation of AMPK in HEK293 cells relative to control,Other,25122135.0,
1699,1189226,1,2,,103164944,338,Unspecified,85681287.0,53632.0,,,Activation of AMPK in HEK293 cells relative to control,Other,25122135.0,
1700,1189226,1,2,,103164944,338,Unspecified,254763436.0,5562.0,,,Activation of AMPK in HEK293 cells relative to control,Other,25122135.0,
1701,1206774,1,2,,103164944,338,Unspecified,74751564.0,134510.0,66000.0,IC50,Inhibition of His6-tagged UBLCP1 (unknown origin) expressed in Escherichia coli BL21 cells using pNPP as substrate at pH 6 at 25 degC by spectrophotometric analysis,Confirmatory,25907364.0,
1702,1208986,1,1,,103164944,338,Unspecified,,,,,Mean Cmax of salicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human,Other,,
1703,1208987,1,1,,103164944,338,Unspecified,,,,,Mean AUC0-t of salicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human,Other,,
1704,1208988,1,1,,103164944,338,Unspecified,,,,,Mean AUCinfinity of salicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human,Other,,
1705,1208989,1,1,,103164944,338,Unspecified,,,,,Mean terminal elimination half-life of salicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human,Other,,
1706,1208990,1,1,,103164944,338,Unspecified,,,,,Mean Tlag of salicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human,Other,,
1707,1208991,1,1,,103164944,338,Unspecified,,,,,Mean Tmax of salicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human,Other,,
1708,1208992,1,1,,103164944,338,Unspecified,,,,,Mean Cmax of salicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human,Other,,
1709,1208993,1,1,,103164944,338,Unspecified,,,,,Mean AUC0-t of salicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human,Other,,
1710,1208994,1,1,,103164944,338,Unspecified,,,,,Mean AUCinfinity of salicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human,Other,,
1711,1208995,1,1,,103164944,338,Unspecified,,,,,Mean terminal elimination half-life of salicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human,Other,,
1712,1208996,1,1,,103164944,338,Unspecified,,,,,Mean Tlag of salicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human,Other,,
1713,1208997,1,1,,103164944,338,Unspecified,,,,,Mean Tmax of salicylic acid concentration after administration of Genuine Bayer Aspirin Tablet at fasting condition in human,Other,,
1714,1209455,1,2,,103164944,338,Unspecified,262527527.0,8647.0,1000.0,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
1715,1209456,1,2,,103164944,338,Unspecified,12585136.0,83569.0,1000.0,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
1716,1209457,1,1,,103164944,338,Unspecified,,,,,Unbound Cmax in human plasma,Other,21965623.0,
1717,1209581,1,2,,103164944,338,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
1718,1209582,1,1,,103164944,338,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
1719,1209583,1,1,,103164944,338,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
1720,1209592,1,1,,103164944,338,Unspecified,,,,,"Dissociation constant, pKa of the basic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
1721,1221780,1,1,,103164944,338,Unspecified,,,,,Cytotoxicity against HEK293 cells expressing UGT1A4 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay,Other,20926620.0,
1722,1221782,1,1,,103164944,338,Unspecified,,,,,Cytotoxicity against HEK293 cells expressing UGT assessed as decrease in cell viability at 1 mM measured up to 72 hrs by MTT assay,Other,20926620.0,
1723,1221821,1,1,,103164944,338,Unspecified,,,,,Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay,Other,20926620.0,
1724,1223488,1,1,,103164944,338,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4",Other,22096083.0,
1725,1223489,1,1,,103164944,338,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake flask method",Other,22096083.0,
1726,1223490,1,1,,103164944,338,Unspecified,,,,,Apparent permeability across human differentiated Caco2 cells,Other,22096083.0,
1727,1223491,1,1,,103164944,338,Unspecified,,,,,Apparent permeability across human differentiated Caco2 cells at 500 uM after 1 hr by HPLC-DAD analysis,Other,22096083.0,
1728,1223492,1,1,,103164944,338,Unspecified,,,,,Oral bioavailability in human,Other,22096083.0,
1729,1224834,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1730,1224834,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1731,1224835,1,1,,144208669,338,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1732,1224835,1,1,,144213426,338,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1733,1224836,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1734,1224836,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1735,1224837,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1736,1224837,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1737,1224838,1,1,,144208669,338,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1738,1224838,1,1,,144213426,338,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1739,1224839,1,1,,144208669,338,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1740,1224839,1,1,,144213426,338,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1741,1224840,3,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1742,1224840,3,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1743,1224841,3,1,,144208669,338,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1744,1224841,3,1,,144213426,338,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1745,1224842,3,1,,144208669,338,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1746,1224842,3,1,,144213426,338,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1747,1224843,1,1,,144208669,338,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1748,1224843,1,1,,144213426,338,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1749,1224844,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1750,1224844,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1751,1224845,1,1,,144208669,338,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1752,1224845,1,1,,144213426,338,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1753,1224846,1,1,,144208669,338,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1754,1224846,1,1,,144213426,338,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1755,1224847,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1756,1224847,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1757,1224848,3,1,,144208669,338,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1758,1224848,3,1,,144213426,338,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1759,1224849,3,1,,144208669,338,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1760,1224849,3,1,,144213426,338,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1761,1224863,1,1,,316919793,338,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1762,1224864,1,2,,316934125,338,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
1763,1224865,1,2,,8139912,338,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
1764,1224867,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1765,1224867,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1766,1224868,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1767,1224868,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1768,1224869,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1769,1224869,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1770,1224870,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1771,1224870,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1772,1224871,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1773,1224871,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1774,1224872,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1775,1224872,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1776,1224873,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1777,1224873,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1778,1224874,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1779,1224874,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1780,1224875,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1781,1224875,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1782,1224876,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1783,1224876,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1784,1224877,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1785,1224877,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1786,1224878,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1787,1224878,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1788,1224879,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1789,1224879,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1790,1224880,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1791,1224880,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1792,1224881,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1793,1224881,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1794,1224882,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1795,1224882,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1796,1224883,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1797,1224883,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1798,1224884,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1799,1224884,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1800,1224885,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1801,1224885,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1802,1224886,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1803,1224886,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1804,1224887,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1805,1224887,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1806,1224888,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1807,1224888,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1808,1224889,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1809,1224889,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1810,1224890,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1811,1224890,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1812,1224892,1,1,,144208669,338,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1813,1224892,1,1,,144213426,338,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1814,1224893,1,1,,144208669,338,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1815,1224893,1,1,,144213426,338,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1816,1224894,1,1,,144208669,338,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1817,1224894,1,1,,144213426,338,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1818,1224895,1,1,,144208669,338,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1819,1224895,1,1,,144213426,338,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1820,1224896,1,1,,144208669,338,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1821,1224896,1,1,,144213426,338,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1822,1236243,1,1,,103164944,338,Unspecified,,,55000.0,IC50,Inhibition of Mycobacterium tuberculosis protein tyrosine phosphatase B expressed in Escherichia coli BL21/DE using pNPP substrate by spectrophotometry,Confirmatory,25505942.0,
1823,1237111,1,1,,103164944,338,Active,,,,,Anti-inflammatory activity in BALB/c mouse model of TPA-induced ear edema assessed as reduction in inflammatory cells infiltration applied topically in combination with curcumin at at 1:1 mol/mol 6 mins before to TPA treatment by H and E staining method,Other,26048786.0,
1824,1237122,1,1,,103164944,338,Active,,,,,Anti-inflammatory activity in BALB/c mouse assessed as reduction in TPA-induced ear edema by measuring weight of ear punches applied topically in combination with curcumin at at 1:1 mol/mol 6 mins before to TPA treatment,Other,26048786.0,
1825,1237124,1,1,,103164944,338,Active,,,,,Anti-inflammatory activity in BALB/c mouse model of TPA-induced ear edema assessed as reduction in inflammatory cells infiltration at 0.75 uM applied topically 6 mins before to TPA treatment by H and E staining method,Other,26048786.0,
1826,1238824,1,1,,103164944,338,Unspecified,,,,,Drug level in human HCT116 cells treated with RAH at 20 uM after 4 to 24 hrs by HPLC-CEAD analysis,Other,26204233.0,
1827,1238825,1,1,,103164944,338,Unspecified,,,,,"Retention time of the compound in C57BL/6J mouse intestine content treated with RAH at 200 mg/kg, ig by HPLC-CEAD analysis",Other,26204233.0,
1828,1238826,1,1,,103164944,338,Unspecified,,,,,"Retention time of the compound in C57BL/6J mouse feces treated with RAH at 200 mg/kg, ig by HPLC-CEAD analysis",Other,26204233.0,
1829,1238827,1,1,,103164944,338,Unspecified,,,,,"Retention time of the compound in C57BL/6J mouse colon treated with RAH at 200 mg/kg, ig by HPLC-CEAD analysis",Other,26204233.0,
1830,1238829,1,1,,103164944,338,Unspecified,,,,,"Retention time of the compound in C57BL/6J mouse urine treated with RAH at 200 mg/kg, ig by HPLC-CEAD analysis",Other,26204233.0,
1831,1238830,1,1,,103164944,338,Unspecified,,,,,"Retention time of the compound in C57BL/6J mouse plasma treated with RAH at 200 mg/kg, ig by HPLC-CEAD analysis",Other,26204233.0,
1832,1252320,1,1,,103164944,338,Active,,,,,Antioxidant activity assessed as DPPH free radical scavenging activity at 0.01 to 1 mM after 30 mins,Other,26183083.0,
1833,1257050,1,1,,103164944,338,Active,115449.0,759.0,9.9,Ki,Inhibition of human carbonic anhydrase 1 incubated for 15 mins prior to testing by stopped flow CO2 hydration assay,Confirmatory,26520662.0,
1834,1257051,1,1,,103164944,338,Active,115456.0,760.0,7.1,Ki,Inhibition of human carbonic anhydrase 2 incubated for 15 mins prior to testing by stopped flow CO2 hydration assay,Confirmatory,26520662.0,
1835,1257052,1,1,,103164944,338,Unspecified,83300925.0,768.0,78.7,Ki,Inhibition of human carbonic anhydrase 9 incubated for 15 mins prior to testing by stopped flow CO2 hydration assay,Confirmatory,26520662.0,
1836,1259241,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1837,1259241,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1838,1259242,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1839,1259242,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1840,1259243,1,1,,144208669,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1841,1259243,1,1,,144213426,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1842,1259244,1,1,,144208669,338,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1843,1259244,1,1,,144213426,338,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1844,1259247,1,1,,144208669,338,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1845,1259247,1,1,,144213426,338,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1846,1259248,1,1,,144208669,338,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1847,1259248,1,1,,144213426,338,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1848,1259309,1,1,,178127199,338,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
1849,1259311,1,1,,178127199,338,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
1850,1259313,1,1,,8139912,338,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
1851,1259318,1,1,,8139912,338,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
1852,1259344,1,1,,144207002,338,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1853,1259364,1,1,,144208669,338,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1854,1259364,1,1,,144213426,338,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1855,1259365,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1856,1259365,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1857,1259366,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1858,1259366,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1859,1259367,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1860,1259367,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1861,1259368,1,1,,144208669,338,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1862,1259368,1,1,,144213426,338,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1863,1259369,1,1,,144208669,338,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1864,1259369,1,1,,144213426,338,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1865,1259377,1,1,,144208669,338,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1866,1259377,1,1,,144213426,338,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1867,1259378,1,1,,144208669,338,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1868,1259378,1,1,,144213426,338,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1869,1259379,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1870,1259379,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1871,1259380,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1872,1259380,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1873,1259381,1,1,,144208669,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1874,1259381,1,1,,144213426,338,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1875,1259382,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1876,1259382,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1877,1259383,1,1,,144208669,338,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1878,1259383,1,1,,144213426,338,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1879,1259384,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1880,1259384,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1881,1259385,1,1,,144208669,338,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1882,1259385,1,1,,144213426,338,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1883,1259386,1,1,,144208669,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1884,1259386,1,1,,144213426,338,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1885,1259387,1,1,,144208669,338,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1886,1259387,1,1,,144213426,338,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1887,1259388,1,1,,144208669,338,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1888,1259388,1,1,,144213426,338,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1889,1259390,1,1,,144208669,338,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1890,1259390,1,1,,144213426,338,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1891,1259391,1,1,,144208669,338,Inconclusive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1892,1259391,1,1,,144213426,338,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1893,1259392,1,1,,144208669,338,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1894,1259392,1,1,,144213426,338,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1895,1259393,1,1,,144208669,338,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1896,1259393,1,1,,144213426,338,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1897,1259394,1,1,,144208669,338,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1898,1259394,1,1,,144213426,338,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1899,1259395,1,1,,144208669,338,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1900,1259395,1,1,,144213426,338,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1901,1259396,1,1,,144208669,338,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1902,1259396,1,1,,144213426,338,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1903,1259401,1,1,,144208669,338,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1904,1259401,1,1,,144213426,338,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1905,1259402,1,1,,144208669,338,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1906,1259402,1,1,,144213426,338,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1907,1259403,1,1,,144208669,338,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1908,1259403,1,1,,144213426,338,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1909,1259404,1,1,,144208669,338,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1910,1259404,1,1,,144213426,338,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1911,1259407,1,1,,363904664,338,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1912,1259408,1,1,,363894970,338,Inactive,,,,,GENE-TOX mutagenicity studies,Other,,
1913,1259411,1,1,,363904664,338,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
1914,1259415,1,1,,8139912,338,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
1915,1259416,1,2,,8139912,338,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1916,1259416,1,2,,340083325,338,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1917,1259416,1,2,,340083326,338,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1918,1259421,1,1,,340083325,338,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1919,1259421,1,1,,340083326,338,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1920,1259423,1,2,,354920810,338,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
